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CHRONIC BEHAVIORAL AND COGNITIVE DEFICITS IN A RAT SURVIVAL MODEL 
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Organophosphates (OPs) are a major class of pesticides and nerve agents that elicit acute 
toxicity by inhibiting acetylcholinesterase (AChE), the enzyme responsible for the degradation of 
the neurotransmitter acetylcholine in the central and peripheral nervous systems. Acetylcholine 
accumulation following extensive AChE inhibition leads to an acute cholinergic syndrome 
characterized by autonomic dysfunction, involuntary movements, muscle fasciculations, 
respiratory distress, and seizures. Despite their classification as moderate to highly toxic, OP 
pesticides are the most widely used class of insecticides in the U.S., and are even more 
commonly used worldwide. Additionally, there is a growing concern that OP nerve agents could 
be used to cause mass civilian casualties. It is well known that the survivors of acute nerve gas 
poisoning and chronic OP pesticide exposure exhibit neurobehavioral deficits including mood 
 
 
changes, depression, and memory impairments. Despite this, there are very few 
treatments available for OP-intoxication survivors and this topic is under-researched. In this 
study we investigated whether animals surviving a single severe OP exposure exhibited long-
term neurological impairments, using two OP agents: paraoxon (POX) and diisopropyl 
fluorophosphates (DFP), as well as a non-OP chemoconvulsant, pilocarpine (Pilo), which acts as 
a muscarinic agonist. Exposure to POX, DFP, or Pilo led to overt signs of cholinergic toxicity. 
POX and DFP rats were rescued with an optimized atropine, 2-PAM, and diazepam therapy per 
current OP-exposure treatment guidelines, while Pilo rats were given only diazepam. Saline was 
administered to control rats at all pharmacological timepoints. Surviving rats were studied using 
established behavioral assays for identifying symptoms of depression and memory impairment 3-
6 months after exposure to toxic agents. In the forced swim test, POX, DFP, and Pilo animals 
exhibited increased immobility time indicative of a despair-like state. In the sucrose preference 
test, POX, DFP, and Pilo rats did not display a preference for sucrose water, indicating an 
anhedonia-like condition. POX, DFP, and Pilo rats also displayed increased anxiety as 
characterized by significantly lower performance in the open arm of the elevated plus maze. 
Furthermore, when tested with a novel object recognition paradigm, POX, DFP, and Pilo rats 
exhibited a significantly lower discrimination ratio, indicating impaired recognition memory. 
The results indicate that these models of survival from severe POX and DFP exposure can be 
employed to study chronic behavioral and cognitive comorbidities and to further investigate the 
molecular bases for these comorbidities, potentially leading to the development of 
pharmacological therapies.  
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CHAPTER 1: INTRODUCTION 
 
 
 
1.1 Organophosphate Pesticides and Nerve Agents  
 
 
History and Epidemiology 
An organophosphate (OP) is defined as an ester of phosphoric acid and is used as the 
basis of many insecticides, herbicides, and nerve agents. OPs were first synthesized between 
1934 and 1944 by the German chemist Gerhard Schrader. He synthesized about 2,000 OP 
compounds at that time, including the pesticide parathion and the nerve agent sarin, more 
commonly known as GB. A number of recent events involving civilian exposure to toxic OPs 
include the use of nerve gas in the recent Syrian civil war, ingestion of OP pesticide 
contaminated school lunches by Indian children resulting in death and severe illness, and the 
weaponization of OP nerve agents paraoxon and parathion during the Rhodesian war [1]. OPs 
used as nerve agents are three to four orders of magnitude greater in acute toxicity than OP 
pesticides, and they are extremely effective as agents of chemical warfare [2]. Sarin, or GB, is a 
man-made OP used historically as a chemical weapon due to its extreme potency and toxicity. 
Sarin has been classified as a weapon of mass destruction and is labeled as a Schedule 1 
substance. Following the use of nerve agents in the Iran-Iraq war in the 1980s, the production 
and stockpiling of chemical warfare agents was outlawed in 162 countries at the Chemical 
Weapons Convention of 1993 [2]. Despite the ban on sarin and similar compounds, OP nerve 
agents continue to be used as weapons. Sarin was used in an act of domestic terrorism in 
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Matsumoto, Japan in 1994, in an attack on the Tokyo subway in 1995, and, most recently, in the 
Syrian Civil War in 2013.  
 
Since World War II, OP pesticides have been widely available as pest-control agents due 
to their relatively low cost and ability to be applied to a wide range of insects and crops. 
According to the CDC, 1.1 billion pounds of pesticides are used annually in the U.S., of which 
OP pesticides make up the majority. OP pesticides are commonly used agriculturally, in public 
recreation areas, and in public health pest control programs such as mosquito eradication [3]. 
Despite their use, the U.S. Environmental Protection Agency (EPA) classifies most OP 
pesticides as moderately to highly toxic. In the U.S., there were more than 8,000 reported 
accidental exposures to OP pesticides in 2008, resulting in approximately 15 deaths [4]. Outside 
of the U.S., exposure to organophosphate pesticides (OPs), whether occupational, accidental, or 
intentional, is a major global health problem. In some countries, rural areas can see hundreds of 
patients poisoned by pesticides each year, with a mortality rate of 50% in the pediatric age group 
and 15-30% in adults [5]. It is estimated that OP compounds account for more than 80% of these 
pesticide-related hospitalizations [6], resulting in up to 300,000 annual fatalities worldwide [7]. 
Although the use of OP pesticides in the U.S. is highly regulated by the EPA, other countries 
often have less stringent regulations for the purchase and use of OP pesticides, as well as less 
public education about the dangers of OP compounds. As a result, 99% of OP-related deaths 
occur in developing countries [5, 7-9].  
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Mechanism and Neuropathology 
Organophosphate pesticides are potent irreversible inhibitors of the enzyme 
acetylcholinesterase (AchE). Under physiological conditions, AchE hydrolyzes the 
neurotransmitter acetylcholine (Ach) into choline and acetic acid after the completion of 
neurochemical transmission. OP compounds bind covalently to the active sites of AchE, 
transforming them into enzymatically inert proteins. Inhibition of AchE leads to the continual 
buildup of Ach at the nerve and neuromuscular synapses. This overabundance of Ach produces 
acute cholinergic symptoms, including salivation, lacrimation, blurred vision, and tremors that, if 
left untreated, may evolve into seizures [10]. Furthermore, individuals exposed to high levels of 
OPs can suffer respiratory depression and rapid death [11]. 
 
Multiple hypotheses have been proposed to account for the neuropathology induced by 
severe OP poisoning. One hypothesis suggests that OPs have a direct toxic effect on brain 
neurons, although there is little experimental evidence to support this. Exposure of cultured 
hippocampal neurons that have been exposed to OPs for 24 h do not produce neurotoxicity [12], 
and direct microinjections of OPs into various brain regions only produces neuropathology if 
seizure activity is also evoked [13].  
 
A second hypothesis emphasizes systemic factors and attributes the pathology to 
hypoxic/anoxic ischemia due to acute respiratory distress caused by OPs. This is largely due to 
research that suggests hypoxia/anoxia/ischemia and prolonged seizure activity produce 
neuropathology through the same final mechanism: the prolonged elevation of intracellular 
calcium ions to neurotoxic levels [14-16]. Despite this, however, several studies have reported 
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that there are minimal changes in p02 in blood or brain preceding [17] or during [18, 19] 
prolonged nerve agent-induced seizures, and one study even suggested that brain p02 levels may 
increase during the first hour of soman-induced seizures in rats [20]. 
 
Finally, the excitotoxic hypothesis emphasizes the role of sustained seizure activity as a 
cause for the development of OP-induced neuropathology. Although some studies have found 
neuropathology following nerve agent exposure in animals that did not have observable 
convulsions during the acute phase of poisoning [21-23], none of these studies used animals 
monitored with EEG recordings. Subsequent work has shown that observable convulsions is not 
a reliable indicator of central seizure activity and that EEG monitoring is essential [24, 25]. 
Additionally, studies with anticonvulsant drugs show that pretreatment with diazepam blocks 
OP-induced seizure activity and prevents the development of neuronal damage entirely [26, 27], 
and that early treatment following OP intoxication may prevent or greatly reduce the severity of 
subsequent neuropathology [11, 13, 25, 27]. Treatment with anticholinergic drugs can also block 
or terminate OP-induced seizure activity and protect against the development of neuropathology 
(150,158,219), as can treatment with glutamate receptor antagonists [11, 18, 28]. All of these 
studies reported that neuropathology was only prevented if the drug treatment stopped all seizure 
activity, however, further supporting the excitotoxic hypothesis of OP-induced neuropathology. 
Additionally, laboratories have examined the effects of allowing rats to experience OP-induced 
seizures for different lengths of time before a treatment was provided to terminate seizure 
activity [11, 29]. Animals that were not given any pharmacological agents to cease seizure 
activity showed moderate to severe brain damage upon histopathological examination. In 
contrast, all animals in whom seizures were controlled within 10 min exhibited no evidence of 
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brain damage. When seizures were controlled after 20 min of active seizures, only 10% of 
animals had visible damage, while 79% of animals had visible damage when seizures were 
controlled after 40 min [30]. This progressive increase in damage associated with active seizure 
time suggests that the neuropathology caused by OP-induced seizures is most likely to be 
associated with excitotoxicity [30]. 
 
Toxicokinetics of Organophosphates 
 The degree of absorption of each OP depends on the amount ingested, the amount 
inhaled, or the contact time with the skin, as well as the lipophilicity of the agent involved, and 
the presence of solvents. Other important factors in exposure include the volatility of the 
pesticide, the permeability of clothing, the extent of coverage of body surface, the age of the 
victim, and the general health of the victim. The rate of absorption also varies with the skin 
region affected. For example, parathion is absorbed more readily through scrotal skin, axillae and 
skin of the head and neck than it is through the skin of the hands and arms [6]. Following 
absorption, OP compounds rapidly accumulate in the liver, kidneys, salivary glands, and fat 
stores. The more lipophilic OPs are stored more extensively in fat, which may lead to prolonged 
intoxication or clinical relapse. OP compounds are generally lipophilic and, in most cases, cross 
the blood/brain barrier [31]. Elimination of OP metabolites occurs mostly in urine with lesser 
amounts in feces and expired air. Depending on the lipophilicity of the OP, the compound may 
be eliminated in hours or may take several days due to extensive fat storage [31].  
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Effects of Chronic Organophosphate Exposure 
Research has been emerging on the effects of both acute and chronic OP exposure. 
Although the U.S. has banned the residential use of OP pesticides, they continue to be used in 
agriculture. OP contamination occurs commonly on produce and can be detected on regularly 
eaten fruits and vegetables, including peaches, apples, grapes, green beans, and pears. 
Inappropriate chronic pesticide exposure is often a problem in poor rural populations of 
developing countries, where men, women, and children all work and live in close proximity to 
fields on which chemicals are applied and stored, leading to excessive exposure and 
unintentional poisoning of its communities and individuals [7]. In fact, it has been estimated that 
99% of all deaths from acute pesticide poisoning occur in developing countries [7]. 
 
Even at relatively low levels, chronic exposure to OPs has been shown to be hazardous to 
the population. Epidemiologic studies of chronic OP exposure display adverse birth outcomes 
including preterm birth, low birth weight, and congenital anomalies, pediatric cancers, 
neurobehavioral and cognitive deficits, and asthma [32]. Multiple case-control studies and 
evidence reviews support a role for OPs in increasing the risk of acute lymphocytic leukemia and 
brain tumors [33]. Prospective contemporary birth cohort studies in the U.S. link early-life OP 
exposure with reductions in IQ and abnormal behaviors associated with attention-
deficit/hyperactivity disorder and autism [34]. Chronic organophosphate-induced 
neuropsychiatric disorders (COPIND) can occur without cholinergic symptoms, and the clinical 
features include anxiety disorder, depression, psychotic symptoms, dysthymic disorder, problems 
with short-term memory, learning, attention, information processing, hand-eye coordination and 
reaction time, and autonomic dysfunction [7, 35-37]. Experimentally, animal models of chronic 
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low doses of OPs display reduced reaction time and decreased accuracy in a spatial learning task 
[38]. Some animal studies have also found cognitive deficits after cessation of low-dose chronic 
OP exposure, some even lasting days or weeks after recovery of AChE activity [39-41]. 
 
Effects of Acute Organophosphate Poisoning 
The effects of acute OP poisoning have also been under investigation. A single acute 
exposure to high doses of OPs can result in immediate, devastating, and even lethal 
consequences. Due to the mechanism of action of OPs, acute OP intoxication manifests clinically 
as acute cholinergic crisis, with peripheral muscarinic symptoms including nausea, vomiting, 
urinary and fecal incontinence, diarrhea, salivation; peripheral nicotinic symptoms including 
muscle fasciculations, paralysis, and hypertension; and central nervous system (CNS) symptoms 
including fatigue, respiratory depression, and unremitting seizures (status epilepticus, SE) [32].  
The clinical manifestations of OP poisoning are outlined in Table 1 [42].  
Table 1.  
Clinical Manifestations of OP poisoning according to receptor type 
Muscarinic Nicotinic Central 
Miosis 
Blurred Vision 
Nausea 
Vomiting 
Diarrhea 
Salivation 
Lacrimation 
Bradycardia 
Abdominal pain 
Diaphoresis 
Wheezing 
Urinary Incontinence 
Fecal Incontinence 
Muscle Fasciculations 
Paralysis 
Pallor 
Muscle Weakness 
Hypertension 
Tachycardia 
Mydriasis (rare) 
Unconsciousness 
Confusion 
Toxic psychosis 
Seizures 
Status Epilepticus 
Fatigue 
Respiratory Depression 
Dysarthria 
Ataxia 
Anxiety 
Tafuri et al, 1987 [42] 
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Human [43-45] and animal [46-49] studies have also linked OP exposure to immediate 
and chronic behavioral changes and altered cognition. In animal models, acute AchE inhibition 
by OPs produced an anxiogenic-like response in the elevated plus maze 48h after injection [50], 
as well as impaired performance in a delayed matching-to-position task 3 weeks after a single 
subcutaneous injection of an OP [51]. Another study showed a dose-dependent decrease in 
performance of a sustained attention task following a single OP exposure [52]. The effects of an 
acute OP intoxication event can persist for weeks, months, and even years. Survivors of the sarin 
gas attack in the Tokyo subway displayed decreased psychomotor skills and alterations in 
behavior indicative of posttraumatic stress disorder as far out as 8 months after the initial 
exposure [53]. Agricultural workers tested 2 years after an acute pesticide poisoning showed 
significantly lower performance in verbal and visual attention, visual memory, sequencing, and 
problem solving [54]. Neurological dysfunction in humans has been observed up to 3 months 
after inhalation of a single dose of sarin, characterized by ataxia, stereotyped behavior and major 
susceptibility to seizures [39]. In victims of acute OP insecticide poisoning, long-term cognitive 
deficits have been observed out to 6 months following exposure [55].  
 
Despite epidemiological data suggesting chronic neuropsychological deficits after acute 
OP intoxication [43, 56-58], this has yet to be tested rigorously in an animal model. There is very 
little data on long-term cognitive, emotional or motivational impairment in animals after acute 
intoxication by OPs [59]. Developing an animal model that would mimic both acute and chronic 
effects of severe OP exposure would be immensely useful in deciphering mechanisms underlying 
the development of chronic morbidities following OP exposure, as well as for the development 
of new therapies.  
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Pharmacological Treatments for OP exposure 
Severe acute OP poisoning is a medical emergency. There is no antidote for 
organophosphate poisoning, although treatment guidelines have been put in place to decrease 
mortality. As OPs irreversibly inhibit AchE, the potent toxicity of OPs is due to excessive Ach in 
the nerve synapse. The two methods of treatment are therefore to either restore AchE activity 
and/or to decrease postsynaptic Ach activity by other means. Restoring AChE activity can occur 
via 1) de-novo biosynthesis of new AchE, 2) slow spontaneous reactivation of the inhibited 
AchE via dephosphorylation, or 3) reactivation of the inhibited AchE as a result of treatment 
with oximes [7]. Oxime compounds, including pralidoxamine (2-PAM), obidoxime, and 
methoxime, bind to, dephosphorylate, and reactivate AchE that has been inhibited by OPs. The 
rate and extent of dephosphorylation of the inhibited enzyme and its subsequent reactivation 
depends on the specific OP used. Oximes are usually used in conjunction with atropine, a 
competitive antagonist of the muscarinic acetylcholine receptors (mAchR), which helps to 
counteract the peripheral effects of excessive Ach. Although atropine remains the mainstay of 
therapy worldwide, other muscarinic antagonists are under investigation.  
 
The therapeutic intervention of OP intoxication has not changed substantially since the 
1950’s [60]. The standard worldwide treatment strategy for acute OP intoxication is a 
combination of 1) an anticholinergic (e.g., atropine) to counteract the acute cholinergic 
syndrome, 2) an oxime (e.g., 2-PAM) to reactive the affected AchE, and 3) an anticonvulsant 
(e.g, diazepam) to treat the seizures and prevent neuropathology [60]. For military medical 
countermeasures against nerve agent poisoning, this standard three-drug regimen is incorporated 
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into auto-injection devices for immediate use in the field [61]. This combination of 
pharmacological agents has proven effective at minimizing lethality of OP poisoning, although 
the ideal dosing regimens have not yet been found [5]. Additionally, while they prove effective 
at decreasing mortality, current treatments lack the ability to prevent post-exposure 
incapacitation, performance deficits, or brain damage [62]. 
 
Pharmacological agents have been developed as a prophylactic treatment to sequester 
highly toxic OPs before they can reach their physiological targets. Given sufficient warning, the 
military employs a pretreatment using a reversible AChE inhibitor (pyridostigmine), the aim 
being to shield a proportion of AChE from irreversible inhibition by nerve agents [61]. 
Additionally, butyrlcholinesterase purified from human plasma (HuBChE) is an enzyme bio-
scavenger that has proven promising as a pretreatment to acute OP poisoning, and is currently 
undergoing clinical trials for future use in humans. Promising data in animal models shows 
pretreatment with HuBChE alone was sufficient not only to increase survivability following 
exposure to multiple median lethal doses of a wide range of potent OPs, but also to alleviate 
manifestation of toxic symptoms in mice and rats without the need for additional post-exposure 
therapy [63]. 
 
Alarmingly, however, there is no current treatment protocol that can be given following 
OP intoxication that both increases survival rates and also prevents brain damage and future 
performance deficits. Although prophylactic bio-scavenger compounds are displaying promising 
results, the fact remains that these compounds must be given prior to any interaction with an OP 
compound. While the success of HuBChE in clinical trials would be exceptionally useful for 
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military personnel undergoing operations with a high risk of OP nerve gas contamination, the 
availability and benefit of these bio-scavenger compounds for the general civilian population is 
limited. In fact, in all recent reported exposures (which have involved civilian casualties), 
treatment - and usually diagnosis - of nerve agent poisoning has been delayed by several hours 
[64, 65]. The global use of OP compounds and their devastating consequences necessitate a great 
need for further study in the area of delayed pharmacological treatment.  
 
1.2 Seizures and Status Epilepticus 
 
Definition and Epidemiology 
Seizures are caused by abnormal electrical activity in the brain that produces a physical 
convulsion, minor physical signs, thought disturbances, or a combination of these symptoms. 
The type of symptoms and seizures depend on where in the brain abnormal electrical activity is 
occurring, the cause of the seizures, and the patient’s health and history. Status Epilepticus (SE) 
is a medical emergency characterized by one seizure lasting 30 minutes or multiple continuous 
seizures without the patient regaining consciousness. This definition has been in place since 
1993, when the American Epilepsy Society Working Group on Status Epilepticus reviewed 
literature suggesting that in experimental models, any seizure that persists for more than 30 min 
is accompanied by serious metabolic decompensation and permanent neuronal damage [66]. If 
left untreated, SE can lead to brain damage and death [67]. An estimated 150,000 cases of SE 
occur annually in the US, with 55,000 associated deaths [68]. The causes for SE include 
preexisting epilepsy, infection, medication changes, metabolic disturbances, anoxia, CNS 
infection, trauma, stroke, and alcohol/pharmacological agents [66].  
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In cases of severe OP poisoning, the victim often experiences respiratory failure, 
depressed levels of consciousness and seizures [69]. These seizures can rapidly progress to SE, 
contributing to mortality, and, in survivors, to neuronal damage and neurological impairment 
[70]. Exact statistics for the percentage of patients exposed to acute OP poisoning that 
experience seizures and SE is difficult to find, for many of these would-be patients die before 
any treatment can be given. In the Matsumoto terrorist attack in Japan, seven people died and 
over 200 sought medical attention [71]. The survivors were critically affected by sarin and 
presented with loss of consciousness and generalized seizures [72-75]. A year later, sarin was 
again used in a terrorist attack in a Tokyo subway. During this incident, 12 victims died and over 
5,000 civilians presented to medical facilities [71]. Only 2.7% of the patients admitted displayed 
seizures, but the concentration of sarin to which most victims were exposed was low and had 
been diluted with a variety of solvents, thereby decreasing its toxicity [70]. Many reports suggest 
that the incidence of seizures following acute OP intoxication is likely to depend strongly on the 
severity and route of poisoning [76, 77].  
 
Pathophysiology of Status Epilepticus 
The pathophysiology of SE is not clearly understood, but excess excitatory (glutamate) 
neurotransmission and loss of normal inhibitory (GABA) neurotransmission are thought to be the 
most likely mechanisms [67]. Both clinical and experimental studies have demonstrated that SE 
can be divided into two phases; the initiation phase and the maintenance phase. During the 
initiation phase, the triggering stimuli evoke multiple discrete seizures, while in the subsequent 
maintenance phase the discrete seizures combine into a continuum, with the triggering stimuli no 
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longer required to sustain the seizure activity [66]. A variety of signaling molecules including 
GABAA antagonists, glutamate agonists, and cholinergic agonists have been found to be 
involved in the initiation phase. In contrast, much less is known about the maintenance phase 
[66]. It has been hypothesized that within the limbic system, the dentate gyrus may act as a 
“gatekeeper” that prevents excitatory stimulation from spreading throughout the hippocampus 
until a point of maximal dentate activation is reached. Once this point has been exceeded, 
excitatory inputs may spread through the hippocampus and then to other areas of the brain [66].  
 
The initiation and continuation of SE may also be in part due to ineffective recruitment of 
inhibitory neurons coupled with excessive neuronal excitation. As the major inhibitory 
neurotransmitter in the CNS, GABA – receptor mediated inhibition may be responsible for the 
normal termination of a seizure. Additionally, glutamate’s activation of the NMDA receptor may 
be required for the propagation of seizure activity. It has been proposed that as the duration of SE 
increases, a mechanistic shift may occur from inadequate GABAergic inhibitory receptor-
mediated transmission to excessive glutamatergic excitatory receptor-mediated transmission [78-
80]. This is further supported by animal research demonstrating that one of the more effective 
pharmacological interventions toward aborting the maintenance stage of SE is through NMDA 
receptor blockade [66]. 
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Pathophysiology of OP-induced Status Epilepticus 
According to a model first proposed by McDonough and Shih, the mechanism of OP-
induced seizures is the result of several different neurotransmitter systems acting sequentially to 
initiate and maintain seizures induced by OPs [52]. Following OP poisoning, the first phase the 
victim experiences is an early cholinergic phase, which lasts from the time of exposure to 5 min 
after seizures onset. During this early phase, an immediate increase in brain Ach levels occurs as 
a result of irreversible inhibition of AchE [81, 82].  
 
The second phase of an OP-induced seizure is a transitional phase of mixed cholinergic 
and non-cholinergic modulation, which lasts until approximately 40 min after the initial onset of 
seizures. During this phase, excitatory activity spreads rapidly to recruit other neurotransmitter 
systems. Microdialysis studies have reported an increase in extracellular concentrations of 
glutamate in the septum, piriform cortex, hippocampal region, and amygdala following OP-
triggered seizures [83, 84]. At the same time, depletion of norepinephrine begins, dopamine 
turnover increases and moderate impairments in GABA function are noted [85-88].  
 
The third and final phase of OP-induced seizures begins after about 40 min following the 
onset of SE, whereupon noncholinergic neurotransmitter systems predominate. Extracellular 
concentrations of ACh return toward normal, while marked increases in dopamine and 
alterations in GABA concentrations are observed [85, 88-90]. Glutamate concentrations remain 
high in some brain areas and choline concentrations are elevated, possibly indicating disruption 
of cellular membranes.  
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Mortality and Morbidity of Status Epilepticus 
Patients who have suffered from SE are prone to several medical complications. 
Numerous clinical studies have demonstrated a relationship between the duration of SE and 
patient mortality [91]. In large hospital-based studies, mortality from SE of any cause varies 
from 3–50%. Increased mortality rates have been associated with acute symptomatic etiologies 
(e.g., hypoxia or central nervous system infections), impairment of consciousness, medical 
complications, age of patient, and overtreatment with antiepileptic drugs (AEDs) [66]. The 
longer the patient is experiencing SE, the more difficult it is to control the seizures with AEDs 
and the greater the degree of neuronal damage [66]. Sustained seizures cause selective neuronal 
loss in vulnerable regions such as the hippocampus, cortex, and thalamus. The degree of 
neuronal injury is closely related to the duration of seizures, underscoring the importance of 
rapid control of SE. Even in the absence of respiratory, cardiac, or metabolic complications, 
ongoing seizures in primates and rats can cause neuronal death [92, 93]. Furthermore, studies 
have reported neuronal loss in the hippocampus and other brain regions in patients with non-
convulsive SE who did not have preexisting seizures or systemic abnormalities [94]. Non-
neurological complications of SE include nosocomial and ventilator-associated pneumonia, 
atelectasis, adult respiratory distress syndrome, neurogenic pulmonary edema, pulmonary 
embolism, hypovolemia, myocardial dysfunction, hypertension, arrhythmias, stress ulcer, 
gastrointestinal bleed, constipation, diarrhea, paralytic ileus, renal dysfunction, urinary tract 
infection, and vascular catheter–related sepsis [66]. 
 
The cognitive and behavioral effects of SE have been under-researched, with the majority 
of data coming from epidemiological studies. Adverse long-term social and education outcomes 
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have been displayed by children that have developed epilepsy after SE [95], and deficits in both 
verbal and nonverbal intellectual ability have been identified following SE [96, 97]. In a 
retrospective study of 239 children that had experienced SE, 57% presented with mental or 
neurological sequelae [98]. More specifically in pediatric SE, 20% of the children developed 
motor delays and 33% presented with IQs lower than 80, although the children all had normal 
development prior to the SE event [98]. In another study, 30% of children showed a neurological 
deficit immediately following SE, and 68% of those children still demonstrated the deficits one 
year later [99]. Animal models of SE also show impaired emotional behavior, increased fear, 
increased anxiety, and hyperactivity [100]. Rats who experienced SE during early development 
had impaired memory 3 months following SE [101, 102].  
 
 
Treatment of Status Epilepticus and OP-Induced Seizures 
Intravenous benzodiazepines (e.g., lorazepam and diazepam) are the first-line drugs for 
treatment of SE, as they potentiate the inhibitory responses mediated by GABAA receptors [103]. 
The efficacy of benzodiazepines, however, dramatically decreases with increasing durations of 
SE [104]. In some cases of prolonged SE, benzodiazepines have little to no effect, and the more 
drastic second-line (phenytoin and fosphenytoin) and third-line therapies (propofol or 
phenobarbital) must be employed, but are not always successful [105]. Animal models are 
currently under investigation to study the pathophysiology of SE and for the discovery of newer 
anticonvulsants.  
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OP-induced SE responds differently to AEDs than other forms of SE [106-108]. Animal 
experiments show that many common anticonvulsants, including phenytoin, phenobarbital, 
lamotrigine, carbamazepine, or valproic acid are ineffective against nerve agent-induced seizures 
[109-111].  This phenomenon has been hypothesized to be due to the wide distribution of the 
cholinergic system throughout the brain, which could limit the effectiveness of drugs that depend 
on reducing the spread of seizure activity [106-108]. Antimuscarinic drugs have been shown to 
be effective in animal models of OP-induced seizures, but they must be administered during the 
initial cholinergic phase of seizures (within ~20 minutes following exposure). As the seizures 
progress and other neurotransmitter systems are recruited, the antimuscarinic drugs become 
ineffective [110, 111]. 
 
Benzodiazepines such as diazepam are the recommended first-line therapy for OP-
exposed patients presenting with seizures [112-115]. It has been recommended that diazepam 
should be administered following all severe OP exposures, even in the absence of behavioral 
convulsions, in case non-convulsive seizures are present  [116]. Alternative benzodiazepines to 
control seizures include lorazepam and midazolam [116]. These drugs act by modulating 
GABAA receptor function to enhance synaptic inhibition in the brain [117, 118]. Due to the 
possibility that diazepam and other benzodiazepines may exacerbate OP-induced respiratory 
depression [119], it has been recommended that a patient's airway and mental status should be 
monitored carefully with this therapy [120]; however, animal studies have suggested that 
diazepam can actually inhibit OP-induced central respiratory depression [121] as well 
as reducing neural damage [122]. This has yet to be confirmed in human patients, however, due 
to ethical reasons.  
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According to the three-phase pharmacological model, anticholinergic drugs will be 
effective for immediate therapy, whereas drugs with anti-glutamatergic effects will be more 
effective following prolonged OP intoxication. Drugs enhancing GABAA neurotransmission (e.g. 
diazepam and other benzodiazepines) may be effective during all phases of nerve agent 
intoxication, but the efficacy may decrease with increasing durations of SE [123]. 
 
Animal Models of Status Epilepticus 
A single seizure is usually of short duration and is self-limiting. During SE, however, 
electrographic seizures occur continuously with poly-spiking [67]. In vivo animal models of SE 
are currently being utilized to elucidate a number of neuropathophysiological mechanisms which 
may underlie how SE may lead to chronic epilepsy, the mechanisms of neuronal injury and 
susceptibility, synaptic reorganization, hippocampal sclerosis, seizure-induced changes in gene 
expression and neurogenesis, and the development of new anticonvulsant drugs [67]. To generate 
these animal models, seizures are induced by either 1) electrical stimulation of brain structures or 
2) chemoconvulsive agents. 
 
Electrical stimulation models were the first series of paradigms to study seizures, SE, and 
neuronal excitability. In the perforant path stimulation (PPS) model, anesthetized rats receive 
repetitive tetanic stimulation of hippocampal afferents such as the perforant path, hippocampus, 
or amygdala to induce SE [67]. While the PPS model allows for SE induction without the 
complications of excitotoxic damage caused by a chemoconvulsant, the required electrode 
implantation is cumbersome and labor intensive.  
 
 
19 
 
 
The most common pharmacological methods to induce SE include kainic acid [124-126] 
and pilocarpine [125, 127-130]. Kainic acid (KA) is a natural marine acid that is a potent 
neuroexcitatory amino acid. KA is an agonist for the kainate receptor, a type of ionotropic 
glutamate receptor. This model has been widely used to investigate temporal lobe epilepsy (TLE) 
and replicates several characteristics of human TLE, including hippocampal sclerosis, cell loss, 
and seizure progression [131]. In rats, intracerebroventricular or systemic administration of KA 
induces the development of SE, which results in damage to the hippocampus, amygdala, piriform 
cortex, entorhinal cortex, septum, and medial thalamus. KA produces robust and persistent 
seizure associated with neuronal damage similar to that found in humans, but a minimal number 
of currently effective AEDs are effective in the KA model, making it a less than ideal model 
[67].  
 
The pilocarpine model of SE-induced TLE is one of the most well-established animal 
models for SE and shares many of the characteristics of human TLE [67, 127, 128]. Pilocarpine 
is a muscarinic cholinergic agonist that induces robust limbic seizures when administered to rats 
[132] via intraamygdaloid injections [133], intrahippocampal injections [134] or systemically by 
intraperitoneal injections [132, 135]. It is thought that pilocarpine initiates SE by cholinergic 
hyperactivation, but that continuation of seizure activity is likely through a glutamatergic 
mechanism [67]. The pilocarpine model of SE is very simple to use and associated with 
prolonged seizures and neurodegeneration [67]. The SE induced by pilocarpine is similar to the 
SE induced by kainic acid, though the site of initial EEG changes in the two models is different. 
Our laboratory has extensive experience with the pilocarpine model of SE [125, 136-139].   
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1.3 Animal Models of Organophosphate intoxication 
To replicate OP intoxication in humans, studies of the mechanisms of OP-induced 
seizures have been performed using animal models, mainly with rodents. Due to the high toxicity 
of OPs, OP-induced seizures with subsequent development of TLE cannot easily be reproduced 
in naive animals without pharmacological adjuncts (e.g. atropine and oximes) to prevent 
immediate mortality [24, 140]. Although pilocarpine has been used to model SE following OP 
exposure, there is a need to establish a SE model that uses an OP compound in order to 
realistically mimic both acute and long-term effects of nerve agent intoxication in humans. 
 
Parathion and Paraoxon 
Paraoxon (POX) is a highly toxic chemical agent that is used in research laboratories as a 
representative OP pesticide. POX is the active metabolite of parathion, a potent OP insecticide 
that has been used as a chemical weapon, most notably during the Rhodesian Bush War. 
Parathion is classified as a Restricted Use Pesticide in the U.S., for use only by certified 
applicators due to its high toxicity, and only in very specific circumstances, but it is still used on 
more than 80 different varieties of crops [141]. Over a dozen countries have banned parathion 
use as a pesticide. Once administered, parathion is converted to POX by the cytochrome P450 
enzyme system, which then binds to and inhibits AchE, thereby leading to an accumulation of 
Ach. POX has been cited as being 50 times more toxic than parathion [141], 70% as potent as the 
nerve agent sarin, and has been used as a weapon by Project Coast, a top-secret chemical and 
biological weapons program instituted by the South African government during the apartheid era 
[141].  
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A specific toxic dose of parathion has not been established in humans. The World Health 
Organization (WHO) has classified parathion as pesticide class Ia (extremely hazardous). 
Poisoning can occur via inhalation and absorption through skin. The rate of poisoning depends 
upon inherent toxicity, dosage, rate of absorption, rate of metabolic breakdown, and prior 
exposure to other cholinesterase inhibitors. Oral doses in the range of 120 – 900 mg have been 
fatal, but humans have also survived much higher doses. In rats, the LD50 for POX has been 
found to be 1800ug/kg orally, 716 ug/kg intraperitoneally, 230ug/kg subcutaneously, 240 ug/kg 
intravenously, and 446 ug/kg intramuscularly [142].  
 
Immediate symptoms of POX exposure in patients can include slurred speech, loss of 
reflexes, and if exposure is high enough, seizures and coma [141]. Acute oral poisoning is often 
accompanied by nausea, cramps, vomiting, diarrhea, and loss of appetite, usually within two 
hours; inhalation may cause wheezing, respiratory distress, bluish skin, miosis, and blurred 
vision. Fatalities are usually caused by respiratory failure or due to unremitting seizures [141]. 
Patients that survive acute POX poisoning may experience long-term effects including 
neuropsychiatric disorders, peripheral neuropathies (nerve cell degeneration), and myopathies 
(muscular degeneration). Disorientation, depersonalization, hallucinations, anxiety and abnormal 
brain patterns may persist for weeks [141]. 
 
In 2014 our laboratory characterized the POX-induced model of SE in the rat [143], 
which was, to our knowledge, the first study that evaluated long-term survival after lethal POX-
induced SE. In this study, rats that were subcutaneously administered POX immediately 
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manifested gross behavioral changes associated with acute cholinergic crisis followed by rapid 
onset of SE. Without antidotal treatment of the cholinergic crisis, death ensued rapidly in all 
POX animals in all but the lowest dosage. In our study, the induction of SE occurred at a dose of 
0.39 mg/kg (95% CL: 0.32–0.47) and the LD50 was 0.85 mg/kg (95% CL: 0.32–2.19). From this, 
we generated a table of dose-dependent effects of POX on SE and mortality (Table 2) [143].   
 
 
Table 2.  
Dose dependent effects of POX on SE and mortality 
Dose of POX (mg/kg, s.c., n = 5-8 % SE % Mortality 
0.1 ± 
0.5± 
0.8± 
1± 
2± 
4 
8 
7 ±2 
42±7 
71±6 
81±4 
90±2 
100 
100 
0 ± 
26±5 
50±6 
88±4 
100 
100 
100 
 
 
 Using the 4 mg/kg dose of POX which resulted in 100% induction of SE and subsequent 
mortality, three regimens of pharmacological intervention were evaluated for effectiveness to 
treat acute OP poisoning. Results from the rest are presented (Table 3) [143]. Although atropine 
(2 mg/kg, saline, i.p.) relieved the cholinergic symptoms and reduced early mortality, the 
progressive AchE inhibition and SE still led to significant mortality. Adding 2-PAM (25 mg/kg, 
saline, i.m.) along with atropine (2 mg/kg, i.p.) lowered mortality yet further, although the 
unremitting seizures led to greater mortality in subsequent days. Finally, diazepam (5 mg/kg, 
i.p.) was administered at 1, 3, and 5-h timepoints following POX (4 mg/kg, s.c.) induced SE, in 
addition to atropine and 2-PAM. The addition of diazepam into the drug regimen increased our 
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survival rate dramatically. From these experiments, we were able to determine the ideal dose of 
POX (4 mg/kg, s.c.), 2-PAM (25 mg/kg, i.m.), atropine (2mg/kg, i.p.), and diazepam (5 mg/kg, 
i.p.) to administer in order to maximize % SE while minimizing mortality for our current and 
future animal studies.  
 
Table 3. 
Role of three-drug regimen in promoting survival following lethal POX intoxication 
Time post SE Percent survival following POX SE in the presence of 
 No drug Atropine Atropine + 2-
PAM 
Atropine + 2-
PAM + diazepam 
1-h± 
24-h± 
48-h± 
72-h± 
0± 
-± 
-± 
-± 
71 ±4 
41±4 
33±6 
12±4 
83±6 
50±6 
41±4 
21±4 
88±4 
83±6 
79±8 
79±8 
N = 8 for no drug condition and n = 24 for each separate drug combination 
 
 
Diisopropyl fluorophosphate (DFP) 
DFP serves as the representative OP used in research laboratories to study nerve agent 
exposure. DFP is a structural homolog of other highly toxic nerve agents, including sarin, and is 
also an irreversible AchE inhibitor. Historically, DFP has been used in combination with mustard 
gas as a means to lower the melting point of mustard gas and to allow for more effective 
distribution in cold weather, a formulation that drove its production during World War II. 
Despite DFP’s structural similarity to more potent nerve agents, it exhibits a markedly reduced 
potency (in terms of lethality) compared to other OPs [144, 145]. DFP is not registered for use in 
the U.S. as a pesticide, but may still be available for use in other countries.  
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DFP is readily absorbed across the lung, mucus membranes, and through the skin. Most 
victims of acute DFP exposure develop symptoms within 6 hours. A toxic dose of DFP has not 
yet been established in humans. Just as with POX, the extent of the poisoning depends upon the 
form of DFP, the dosage, rate of absorption, rate of metabolic breakdown, and prior exposure to 
other AchE inhibitors. The LD50 for DFP in rats has been found to be 6 mg/kg orally, 1280µg/kg 
intraperitoneally, 14.5 µm/kg subcutaneously, and 1800 µg/kg intramuscularly [146]. Just as 
with acute POX intoxication, immediate effects of DFP intoxication in the human population 
include bradycardia, salivation, lacrimation, diaphoresis, vomiting, urination, diarrhea, and 
miosis. In severe cases, effects include respiratory failure, CNS depression, agitation, coma, and 
seizures. Just as with POX, fatalities are usually caused by respiratory failure or due to 
unremitting seizures [141].   
 
Due to its less toxic effects, DFP has been used extensively to study OP intoxication in 
the research setting. If exposed to chronic low levels of DFP, rodents exhibit behavioral 
pathologies which include impaired performance in passive avoidance tasks [147], affected new 
learning in a spatial navigation task [40], affected reaction time in the Y-maze [39], and impaired 
working memory weeks after the final DFP dosing [40]. Similar to POX, our lab has recently 
characterized a model of DFP-induced SE [137], demonstrating the mortality, behavioral 
manifestations, and EEG profile for DFP-induced SE. From these dose-dependent studies, we 
decided to use an improved dosing regimen of DFP (4 mg/kg, s.c.) with a treatment of 2-PAM 
(25 mg/kg, i.m.), atropine (2mg/kg, i.p.), and diazepam (5 mg/kg, i.p.) to maximize survival rates 
for future studies of OP exposure (Table 4). 
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Table 4.  
Dose dependent effects of DFP on seizures and mortality 
Dose of DFP (mg/kg, s.c)  
in ice-cold PBS 
% displaying 
seizures 
% Mortality 
1  
2 
2.5 
4 
5 
1 
10 
30 
50 
90 
100 
100 
0  
0 
5 
10 
80 
90 
 
1.4 Behavioral Assays 
Animal models provide valuable tools with which to study human behavior, to 
investigate molecular mechanisms, and to serve as a screening tool for new therapies. Our 
laboratory is interested in investigating whether the long-term behavioral changes and cognitive 
impairments found epidemiologically in survivors of acute OP poisoning also exist in animal 
models of OP-induced SE. We therefore chose to focus on behavioral assays that would allow us 
to characterize depression-like behavior and cognitive impairment in animals that survive OP-
induced SE.  
 
 Multiple assays must be used to characterize depression-like behavior. The DSM-IV 
diagnoses a patient as having experienced a major depressive episode if five or more of the 
following depressive symptoms have occurred within a two week period: (1) depressed mood, 
(2) anhedonia, (3) weight or appetite changes, (4) sleep changes, (5) psychomotor agitation or 
retardation, (6) fatigue, (7) feelings of worthlessness, (8) inability to concentrate, (9) recurrent 
thoughts of death or suicidal ideation. Additionally, one of the five symptoms experienced must 
include either depressed mood or anhedonia. A variety of assays are utilized to model this 
behavior in animal models, including the sucrose preference test (SPT) to model anhedonia, the 
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forced swim test (FST) to model behavioral despair, and the elevated plus maze (EPM) to model 
anxiety. We chose to perform the novel object recognition test (NORT) to test for memory 
impairment. Although additional behavioral assays may be used, we chose to administer these 
four behavioral assays, as they are relatively easy to administer, not unnecessarily stressful to the 
animal, and well-characterized in the literature. 
 
Sucrose Preference Test 
Anhedonia is a core symptom of depression, as either anhedonia or depressed mood is 
required for a classification of a major depressive episode, and is defined as the inability to 
experience pleasure from activities previously found enjoyable, such as exercise, hobbies, sexual 
activities, or social interactions. The SPT is an accepted method of assessing anhedonia in 
rodents, and has been in use since it was first characterized in the 1980’s [148]. Decreased 
performance in the SPT has been observed in a mouse genetic model of depression, as well as 
under conditions of depression induced by a chronic mild stress animal model [149]. 
Additionally, altered SPT preference in a chronic stress model was returned to normal after 2-4 
weeks of treatment with an antidepressant [148] .  
 
In the SPT, animals are given the choice to drink from a bottle containing a sucrose 
solution or from a bottle containing regular drinking water. Under normal conditions, rats 
naturally prefer to drink a sucrose-containing solution over regular water. In animals that are 
experiencing anhedonia, however, there is no preference for the sucrose solution, and the animals 
do not discriminate between the two solutions [149]. Taste preference is expressed as a 
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percentage of the volume of sugar solution consumed divided by the total volume of liquids 
consumed during the test period.  
 
Elevated Plus Maze 
 Anxiety is a symptom with high prevalence in depression. In the literature, it is 
commonly believed that anxiety and depression are interrelated phenomena [150]. In animals, 
anxiety is described as an emotional state with sustained autonomic and behavioral arousal, and a 
sustained increase in avoidance behavior. It is assumed that, evolutionarily, animals were shaped 
by natural selection to display fear or anxiety-mediated responses to specific stimuli. For 
example, naturally aversive situations for rodents include being in an unfamiliar open space and 
exposure to heights or to bright light [150]. All of these features are incorporated in and form the 
basis of exploratory tests for anxiety responses. The EPM is one of the most used tests to assess 
anxiety-like levels of rodents [151], and has been in use since the 1980’s, when it was first 
developed to screen for anxiety effects of drugs [152]. Furthermore, the anxiety-like behavior 
displayed in the EPM can be reversed by anxiety-reducing pharmacological agents [152].  
 
In the EPM, the animal is subjected to an unknown environment: a maze that is raised off 
the ground in a plus shape. Two arms are open and exposed, while two arms are enclosed by 
high walls. The EPM contrasts rodents’ fear of novel, brightly lit spaces that may be potentially 
dangerous against natural rodents’ proclivity to explore novel environments [153]. Anxiety-like 
behavior can therefore by assessed by comparing the ratio of time spent in the open arms of the 
EPM with the time spent in the closed arms. Animals that are exhibiting anxiety-like behavior 
will spend more time hidden in the closed arms of the EPM while avoiding the novel open arms.  
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Forced Swim Test 
 The depression-like symptom of behavioral despair is assessed by the FST, first 
characterized by Porsolt et al. in the 1970’s [154]. Decreased performance in the FST has been 
observed in genetic models of depression in both rats and mice, in animals with depression 
induced by maternal separation, and in animals with depression induced by chronic food 
restriction [149]. It is one of the most widely used tools in depression research, used most 
commonly for screening of acute antidepressant efficacy, as the increase in immobility time can 
be reversed by the acute administration of almost all available antidepressants [154, 155].  
 
In this assay, the animal is placed in a container of room temperature water, which 
represents an inescapable stressor. The FST therefore creates a situation of behavioral stress, and 
allows the animal to exhibit active escape behavior. The premise of the FST is based on the 
interpretation that immobility in the water is a passive stress-coping strategy or depression-like 
behavior. Animals that show increased immobility, where the animal moves only enough to keep 
his nose above the water to avoid drowning, is indicative of a depression-like state [156, 157].  
 
Novel Object Recognition Test 
The NORT is a highly validated test for recognition memory that has been used 
consistently since the late 1980’s. It can be used to study memory and learning, preference for 
novelty, the influence of different brain regions in the process of recognition, and even the study 
of different drugs and their effects [158]. The NORT evaluates the animal’s ability to recognize a 
previously presented stimulus. There is no overt reward; instead, it is the rodents’ innate 
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exploratory behavior and propensity for novel objects that drives the assay. Additionally, 
minimal training and habituation is required, and it can be completed with minimal stress to the 
animal.  
 
During the NORT, animals are individually given a period of time to habituate to the 
empty test environment. On the first phase of test day (sample phase), two identical objects (A) 
are placed in opposite corners of the box, and the rat is allowed to explore for a small amount of 
time before it is removed and returned to its home cage. After some time (1h – 3h later), one of 
the familiar objects (A) is replaced with a novel object (B), and the rat is placed back inside the 
test environment and allowed to explore. Objects are similar in size and emotionally neutral, but 
varied in color, shape, and texture. The discrimination ratio measures the novel object 
exploration, and is calculated by: (Novel – Familiar) / (Novel + Familiar) [158]. The 
discrimination ratio varies between + 1 and -1, with a positive ratio signifying more time spent 
exploring the novel object, indicating that the animal remembered the familiar object. A negative 
ratio reflects more time spent with the familiar object, indicating that the animal did not 
remember previous exploration of the familiar object. A ratio of 0 indicates that equal time was 
spent exploring both the novel and familiar object [158].  
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CHAPTER 2: SUMMARY AND PROJECT OBJECTIVES 
 
Since their initial synthesis in the 1930’s, OP pesticides have been utilized in agriculture 
and in public health pest control programs such as mosquito eradication due to their effectiveness 
and relatively low cost. Despite their classification as moderate to highly toxic, OP pesticides 
remain the most widely used class of insecticides in the US, although their use is highly 
regulated. Worldwide, OP pesticide exposure is a large global health problem, with an annual 
fatality rate of up to 300,000 and 99% of all OP pesticide poisoning cases occurring in 
developing countries. Additionally, OP nerve agent attacks have been occurring worldwide for 
the past several decades, producing hundreds of thousands of victims and leaving survivors with 
chronic health deficits and behavioral changes.  
 
As irreversible inhibitors of AchE, poisoning by OP compounds leads to excessive Ach 
which produces symptoms of acute cholinergic crisis. If left untreated, these symptoms can lead 
to seizures, coma or death. The symptoms of a single acute OP intoxication event have been 
found to persist in survivors for weeks, months, and even years. These survivors display altered 
behaviors including depression, PTSD, decreased performance in verbal and visual memory, 
increased susceptibility to seizures, and cognitive deficits. Despite the epidemiological data, 
there are few treatments available for survivors of OP intoxication. The current treatment 
protocol for acute OP intoxication helps only with acute lethality, and has no effect on 
preventing or minimizing brain damage and future performance deficits. There is very little data 
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on possible pharmacological treatments for these behavioral deficits, and no current animal 
model exists to help model chronic neurobehavioral changes after acute OP intoxication. The 
aim of this study was therefore to characterize an animal model of chronic behavioral and 
cognitive deficits following acute organophosphate toxicity.  
 
Paraoxon (POX), the active metabolite of parathion, is a highly toxic chemical agent that 
is used in research laboratories to study OP-induced toxicity. Our laboratory has previously 
characterized the POX-induced model of SE in the rat, and has optimized a dosing and treatment 
protocol to maximize seizure rates while minimizing mortality. Diisopropyl fluorophosphates 
(DFP) is a structural homolog of highly toxic nerve agents, and can be more safely studied in 
research laboratories than other, more toxic, nerve agents. Research has shown that chronic low 
levels of DFP have led to impaired memory, but to our knowledge the long-term effects of a 
single acute high-dose DFP intoxication have not yet been characterized. Just as with POX, our 
lab has developed a model of DFP-induced SE in the rat, optimizing a dosing and treatment 
protocol to maximize seizure rats and minimize mortality. Additionally, we have extensive 
experience with a pilocarpine-induced model of SE in the rat, which has previously been shown 
in the literature to display chronic behavioral abnormalities and cognitive impairment. 
Pilocarpine is not an organophosphate-based compound, but a cholinergic M1 receptor agonist 
that results in SE through the same final mechanism as POX and DFP; that is, inducing a 
cholinergic crisis.  
 
Due to our laboratory’s extensive research with POX and DFP, in conjunction with the 
overwhelming epidemiological data of the chronic behavioral and cognitive effects of a single 
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acute OP intoxication event, the next logical step was to characterize whether these chronic 
behavioral changes are also seen in animal models of acute OP intoxication. If so, these animal 
models would be beneficial in investigating the molecular mechanisms behind chronic 
behavioral changes following acute OP intoxication and for developing novel pharmacological 
treatment therapies.  
 
Our central hypothesis is that “Rats that survive pilocarpine and OP-induced SE will 
exhibit chronic depression-like behavior and memory impairment.” The following specific 
aims are designed to test this central hypothesis.  
 
 Aim 1: Determine whether animals that have been exposed to Pilo, POX or DFP-induced 
SE exhibit chronic depression-like behavior. 
 Aim 2: Determine whether animals that have been exposed to Pilo, POX or DFP-induced 
SE exhibit chronic memory impairment.  
 
  To determine whether animals that have been exposed to Pilo, POX or DFP-induced SE 
exhibit chronic depression-like behavior, we subjected animals to the sucrose preference test to 
measure anhedonia, the elevated plus maze to measure anxiety, and the forced swim test to 
measure behavioral despair. To determine whether animals that have been exposed to Pilo, POX 
or DFP-induced SE exhibit chronic memory impairment, we subjected animals to the novel 
object recognition test to measure recognition memory. Pilo-induced SE animals were also 
subjected to all behavioral assays as a previously characterized model of chemoconvulsant-
induced SE, as a positive control for OP compounds.  
 
 
33 
 
 
 
CHAPTER 3: MATERIALS AND METHODS 
 
 
3.1 Animals  
All protocols utilize adult male Sprague–Dawley rats (Harlan; wt.: 250-300 g, age: 8-9 
weeks)  which are used in strict accordance with the National Institute of Health Guide for the 
Care and Use of Laboratory Animals and approved by Virginia Commonwealth University's 
Institutional Animal Care and Use Committee. Animals are housed in single cages on a 12-h/12-
h light/dark cycle and provided food and water ad libitum.  
 
3.2 Chemicals 
All chemicals used were obtained from Sigma Aldrich Company (St. Louis, MO) unless 
otherwise specified. POX was dissolved in ice-cold phosphate buffered saline (PBS) just before 
the experiment and kept on ice until injected subcutaneously (s.c.). Atropine and 2-PAM were 
dissolved in saline (0.9% NaCl) the morning of the experiment. Diazepam, in injectable liquid 
form, was obtained from the VCU Health System Pharmacy. DFP was supplied as an oily 
solution which was also dissolved in ice-cold PBS just before the experiment and kept on ice 
until injected subcutaneously (sc). Pilocarpine and scopolamine methyl nitrate were dissolved in 
saline (0.9% NaCl) the morning of the experiment.  All other drugs were prepared fresh on the 
day of the experiment. 
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3.3 Pilocarpine-induced SE 
Pilocarpine (Pilo) is a cholinergic muscarinic agonist that, in rodents, leads to SE and 
ultimately epilepsy with SRSs and hippocampal pathologies similar to human patients with TLE 
[128]. SE is induced using a modified protocol that is well established in our laboratory [125]. 
Scopolamine methyl nitrate (1mg/kg, i.p.) is administered 30 minutes before the injection of 
pilocarpine (375 mg/kg, i.p.) to block peripheral cholinergic over-activation and minimize 
mortality [159]. Following injection of pilocarpine (375 mg/kg, i.p.), the onset of SE occurs 
within 20-30 minutes. Diazepam (5mg/kg, i.p.) is administered at 1 h, 3 h, and 5h post-SE onset 
to terminate seizure activity. Sham animals receive only saline injections at all pharmacological 
timepoints. Animal health was monitored over the next five days and veterinary care and saline 
solution provided if weight gain did not occur. By the fifth day all surviving animals had 
recovered from Pilo-induced cholinergic crisis and were independently mobile. Animals were 
then housed individually in a temperature and light controlled vivarium, where they were 
weighed and visually monitored weekly until their use in behavioral experiments.   
 
3.4 POX-induced SE 
Rats were injected with POX (4 mg/kg, s.c.), followed one minute later by pralidoxime 
(2-PAM, 25 mg/kg, i.m., an AchE reactivator) and atropine sulfate (2 mg/kg, i.p., a competitive 
antagonist of muscarinic receptors), which are employed by U.S. Army as countermeasures 
against nerve gas intoxication [160, 161]. Within minutes, rats began exhibiting classic hyper-
cholinergic symptoms, including respiratory distress, increased salivation, defecation, urination, 
and tonic-clonic seizures. To mimic the time required for emergency personnel to reach the site 
 
 
35 
 
of OP release and begin treatment of exposed individuals, rats were administered an optimized 
FDA-approved treatment regimen of diazepam (5 mg/kg, i.p.) and 2-PAM (25 mg/kg, i.m.) at 1h 
post-SE. Given the short half-life of 2-PAM, and to prevent seizures from reoccurring, the 
injections were repeated at 3h and 5h post SE. At the end of all injection, surviving animals were 
given 3mL saline solution (i.p.) and sucrose milk (p.o.).  Sham animals were given saline at each 
pharmacological time point. Animal health was monitored over the next five days and veterinary 
care and saline solution provided if weight gain did not occur. By the fifth day all surviving 
animals had recovered from POX-induced cholinergic crisis and were independently mobile. 
Animals were then housed individually in a temperature and light controlled vivarium, where 
they were weighed and visually monitored weekly until their use in behavioral experiments.   
 
3.5 DFP-induced SE 
 All experimental rats received pretreatment with pyridostigmine bromide (0.026 mg/kg, 
im) 30 min before DFP (4 mg/kg, s.c.) injection. One minute following DFP injection, animals 
received 2-PAM (25 mg/kg, im) and atropine (2 mg/kg, ip). These treatments approved by the 
Food and Drug Administration are employed by U.S. Army as countermeasures against nerve 
gas intoxication (Broomﬁeld and Kirby, 2001; Golomb, 2008). Rats underwent convulsions and 
SE-like activity within 7–10 min following DFP. If the animals went into SE and survived 1 h of 
seizure activity, they were injected with diazepam (5 mg/kg, ip) and 2-PAM (25 mg/kg, im) at 1, 
3, and 5 h following SE onset to terminate and control seizures. Sham animals received saline at 
all pharmacological timepoints. Animal health was monitored over the next five days and 
veterinary care and saline solution provided if weight gain did not occur. By the fifth day all 
surviving animals had recovered from DFP-induced cholinergic crisis and were independently 
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mobile. Animals were then housed individually in a temperature and light controlled vivarium, 
where they were weighed and visually monitored weekly until their use in behavioral 
experiments.   
 
3.6 Behavioral Assays 
 
Depression is a complex psychological phenomenon, and is difficult to analyze using a 
single test [162]. The combination of helplessness and despair, anxiety, and anhedonia constitute 
the symptoms of a depression-like state in rats. We therefore administered the forced swim test 
(FST) which models despair, the sucrose preference test (SPT) which models anhedonia, and the 
elevated plus maze (EPM), which measures anxiety. To test memory, we utilized the novel 
object recognition test (NORT). Rats were first subjected to the SPT, followed by the NOR, 
EPM, and finally, the FST. The order of behavioral assays administered was from least stressful 
to the most stressful, and no two assays were performed on the same day. Vehicle-administered 
age-matched controls were utilized to minimize behavioral changes due to handling or stress. For 
each chemoconvulsant, the treatment group was assessed on the same day as the control group 
(i.e. POX animals with their age-matched controls, DFP animals with their age-matched controls, 
and Pilo animals with their age-matched controls), and multiple treatment groups were not 
assessed on the same day (i.e. testing of POX animals was not done on the same day as DFP 
animals).  
 
The specific order of animal testing was chosen at random, and multiple blinded 
researchers scored each behavioral assay. All trials for each behavioral assay were performed in 
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the same room with the same lighting and minimal noise levels throughout testing. All 
behavioral assays were performed between 0800 and 1400h. Between animals, apparatuses were 
cleaned with a 30% ethanol solution to minimize olfactory cues. The body weight of each animal 
was measured just prior to administration of the chemoconvulsant and the day before behavioral 
testing. There was no significant difference in body weights between controls and the 
chemoconvulsant groups at each time point (Table 5). 
 
 
Table 5. Animal body weights (g)  
 
Before SE 
Day 0 of 
Behavioral 
Testing 
Control 298.7 ±5.7 528.0 ±18.5 
POX 309.3 ±4.3 515.0 ±26.61 
Control 277.9 ±5.3 533.2 ±19.8 
DFP 283.1 ±3.2 525.3 ±25.3 
Control 285.0 ±2.0 545.25 ±21.12 
Pilo 283.5 ±1.9 524.86 ±32.0 
 
 
 
Sucrose Preference Test 
The sucrose preference test (SPT) is an established method for assessing anhedonia, or 
loss of interest, in rodents [149, 162]. The SPT utilizes the rats’ natural inclination for sweets to 
measure their preference for sugar water over regular drinking water [149, 162, 163]. Lower 
levels of sucrose consumption and sucrose preference in animals can be interpreted as an 
anhedonia marker, which is reversible with chronic antidepressant treatment [149, 162, 163]. 
Prior to the experiment, animals were housed individually and receiving food and water ad 
libitum, but only had one water bottle in each age. We introduced a second water bottle into each 
animal’s cage for three days for the animal to acclimate to the presence of two drinking bottles. 
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The bottles were fitted with ball-bearing sipper tubes that prevented fluids from leaking. 
Following this acclimation, one bottle was, at random, replaced with 300ml of a 1% sucrose 
solution. The other bottle was filled with 300ml of fresh water. 24 hours later, the positions of 
the bottles were switched to avoid a side-preference, and 48 hours later the amount of liquid left 
in each bottle recorded. Taste preference was calculated as the percentage of the volume of sugar 
solution consumed over the total volume of fluid consumed (sugar plus water) over a 24 hour 
period. A lack of preference for the palatable sucrose solution (i.e. drinking equally from both 
the sucrose solution and the regular water solution) is considered to be an index of anhedonia 
[164]. 
 
Elevated Plus Maze 
The elevated plus maze (EPM) exploits a rodent’s conflicting desire to explore novel 
surroundings against its baseline fear of heights and open spaces [153]. The maze (Med 
Associates Inc) is made of black polyvinyl chloride and consists of four arms, 50 cm long x 10 
cm wide, connected by a central square that is 10 x 10cm. Of the four arms, two are open without 
walls and two are closed by 31cm high walls. All arms are attached to sturdy metal legs, and the 
entire maze is elevated 55 cm above the floor and set in a dimly lit room. A video camera was 
suspended above the maze to record animal movements (Noldus Ethovision XT 9), which was 
used to collect and analyze behavioral data. Each animal was placed at the center junction of the 
open and closed arms, facing the open arm opposite to the experimenter. The behavior of each 
animal was recorded for 5 min. At the end of the 5 min test, the animal was removed from the 
elevated plus maze and returned to its home cage. The maze was cleaned with 30% ethanol and 
allowed to dry completely before introducing the next animal into the arena. Anxiety-like 
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behavior can be assessed by comparing the ratio of time spent in the open arms versus the time 
spent in the closed arms. An increase in the open-arm time is indicative of anti-anxiety behavior, 
while an increase in closed-arm time is indicative of anxiety-like behavior [165]. 
 
Forced Swim Test 
We used Porsolt’s modified forced swim test (FST) to assess behavioral despair [149, 
162, 166], whereupon animals were forced to swim in a glass cylindrical chamber (46cm H x 
30cm D) filled with water (30 cm height, 25°C). Thermometers were used to ensure that the 
water temperature was a constant 24-26°C for all animals. Two swimming sessions were carried 
out, one as an initial 15 min ‘pre-test,’ followed 24 hours later by a second 5 min ‘test.’ Test 
sessions were video recorded and the duration of active (swimming, climbing, diving) and 
passive (immobility) behavior was recorded multiple times by two reviewers blinded to the 
treatment conditions. The % immobility was calculated for each experimental group. Immobility 
is defined as the period during which the animal floats in the water, making only those 
movements necessary to keep its head above water [167-169]. Increased immobility/decreased 
active swimming is interpreted as despair, while a reduction in immobility/increase in active 
swimming is indicative of an anti-depressant effect [166].  
 
Novel Object Recognition Test 
Rats were placed individually into a black Perspex box 60cm x 90 cm x 50 cm in a dimly 
lit and quiet animal behavior testing room. Each rat was given a daily habituation period of 15 
min per session in the empty arena for three days. On the fourth day, during the first phase 
(sample phase), two identical objects (A) were placed in opposite corners of the box, each object 
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20 cm from the wall. The rat was allowed to explore for 3 min before it was removed from the 
box and returned to its home cage. During the second phase (choice phase) 3 h later, one familiar 
object (A) was replaced by a novel object (B), and the rat was allowed to explore for 2 min. 
Objects were similar in size and emotionally neutral, but varied in color, shape, and texture. 
Behavior was recorded by a digital camera mounted above the experimental box, and researchers 
blinded to treatment conditions analyzed the data for object interaction. Object interaction 
included any contact with mouth, nose, or paw, but did not include interactions that were 
accidental (bumping into the object). Additionally, leaning, sitting, or standing on the object was 
not included as interaction. The discrimination ratio is calculated by: (Novel – Familiar) / (Novel 
+ Familiar [158]. The discrimination ratio varies between + 1 and -1, with a positive ratio 
signifying more time spent exploring the novel object, a negative ratio indicating more time 
spent with the familiar object, and a ratio of 0 indicating that equal time was spent exploring both 
the novel and familiar object. [158, 170]. 
 
3.7 Statistical Analysis 
For all behavioral assays, statistical analysis is performed using a one-way analysis of 
variance (ANOVA) followed by a Tukey–Kramer post hoc test for differences between 
individual groups. 𝑃< 0.05 is considered to be statistically significant. All statistical analyses are 
performed using SigmaPlot v.12.3. 
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CHAPTER 4: RESULTS 
 
 
In humans, the diagnosis of depression is based on the presence of reported symptoms 
and not on any quantifiable lab tests. Since we cannot identify these emotional symptoms in 
rodents, we must instead rely on behavioral assays that model different aspects of depressive 
symptoms. Our studies aimed to identify the following symptoms of depression: anhedonia 
(SPT), behavioral despair (FST), and anxiety (EPM). We aimed to measure memory deficits 
using the NORT.  
 
4.1 Depression-Like Behavior 
Elevated Plus Maze 
The EPM demonstrated increased anxiety in POX, DFP, and Pilo intoxicated rats. POX 
(4 mg/kg), DFP (4 mg/kg), and Pilo (375 mg/kg) rats spent significantly less time exploring the 
open arms (% open arm time , Fig. 1A) and entered the open arms fewer times (% open arm 
entries, Fig. 1B) when compared to age-matched control rats. No differences were observed in 
the total distance traveled (Fig. 1C), nor in the number of total arm entries (Fig. 1D) between 
each group. This data suggests that although animals that experienced SE traveled the same total 
distance and explored the maze the same amount as control animals, POX, DFP, and Pilo-treated  
animals explored the open arms significantly less, preferring instead to hide in the closed arms of 
the EPM, suggesting anxiety-like behavior.  
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Figure 1.  
The Elevated Plus Maze (EPM) showed increased anxiety in POX, DFP, and Pilo intoxicated 
rats. POX (4 mg/kg), DFP (4 mg/kg), and Pilo (375 mg/kg) rats displayed significantly less 
time exploring the open arm time (A) and had fewer open arm entries (B) as compared to 
age-matched control rats. No differences were observed in the total distance traveled (C), nor 
in the number of total arm entries (D) between each group. Data expressed as mean ± SEM, * 
p < 0.05, t-test, n=8 
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Sucrose Preference Test 
Baseline water consumption for the SPT was equal for POX (4 mg/kg) compared to age-
matched controls (Fig. 2A), DFP (4 mg/kg) compared to age-matched controls (Fig. 2B), and 
Pilo (375 mg/kg) compared to age matched controls (Fig. 2C). There was no significant 
difference in side-preference for water consumption in any of the groups. When one bottle of 
water was replaced with a 1% sucrose solution, POX (Fig. 3A), DFP (Fig. 3B), and Pilo (Fig. 
3C) animals did not show a preference for the sucrose solution, although their age-matched 
controls overwhelmingly preferred the sucrose solution. Additionally, during the test phase, the 
total fluid consumed (Sucrose + Water) was not significantly different between controls and 
POX rats (Fig. 4A), controls and DFP rats (Fig. 4B), or controls and Pilo rats (Fig. 4C). This 
suggests that although SE animals drank the same total amount of fluid as the control animals in 
both the baseline and test phases, they did not show a preference for the sucrose water, indicative 
of an anhedonia-like state.  
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Figure 2.  
Baseline water consumption for the Sucrose Preference Test (SPT) was equal for POX  
(4mg/kg) compared to age-matched controls (A), DFP (4 mg/kg) compared to age-matched 
controls (B), and Pilo (375 mg/kg) compared to age matched controls (C). There was no 
significant difference in side-preference for water consumption in any of the groups. Data 
expressed as mean ± SEM, * p < 0.05, t-test, n=8 
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Figure 3.  
Loss of sucrose consumption preference in the Sucrose Preference Test (SPT). Of the total 
liquid consumed during the test, controls overwhelmingly consumed 1% sucrose solution 
over regular water, whereas (A) POX (4mg/kg), (B) DFP (4mg/kg), and (C) Pilo (375 
mg/kg) rats did not exhibit any significant preference for sucrose water or regular water, 
indicating anhedonia-like behavior. Data expressed as mean ± SEM, * p < 0.05, t-test, n=8 
per group 
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Figure 4.  
The total fluid consumed during the Sucrose Preference Test (Sucrose + Water) was not 
significantly different between (A) controls and POX (4mg/kg) rats, (B) controls and DFP 
(4 mg/kg) rats, or (C) controls and Pilo (375 mg/kg) rats. Data expressed as mean ± SEM, * 
p < 0.05, t-test, n=8 per group 
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Forced Swim Test 
The FST was effective in evaluating the presence of a despair-like state in the POX (4 
mg/kg), DFP (4 mg/kg), and Pilo (375 mg/kg) intoxication survival model. POX, DFP, and Pilo 
toxicity survivor rats subjected to the modified FST exhibited increased immobility time that was 
significantly higher when compared to the immobility time in age matched control rats (Fig. 5). 
The decrease in active swimming and increase in floating and immobility time displayed by the 
POX, DFP, and Pilo-treated rats is indicative of despair-like behavior.  
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Figure 5.  
Immobility time in the Forced Swim Test (FST) for POX (4mg/kg), DFP (4 mg/kg), and 
Pilo (375 mg/kg)-treated rats was significantly higher compared to age-matched control 
rats, indicative of despair-like behavior. Data expressed as mean ± SEM, * p < 0.05, t-test, 
n=8 per group 
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4.2 Cognitive Impairment 
 
Novel Object Recognition Test 
During the sample phase, there was no significant difference in baseline exploratory 
behavior of POX (4 mg/kg), DFP (4 mg/kg), or Pilo (375 mg/kg)-exposed rats when compared to 
their age-matched controls (Fig 6A). In the choice phase, each chemoconvulsant’s age-matched 
control rats spent more time exploring the novel object than the familiar object, indicating a 
memory for previous exploration of the familiar object. In contrast, POX, DFP, and Pilo rats 
displayed a significantly lower discrimination ratios when compared to age-matched control rats. 
In other words, SE rats did not explore the novel object more than the familiar object, indicating 
impaired recognition memory for the familiar object during the sample phase of the test (Fig 
6B). 
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Figure 6.  
Impaired recognition memory in POX (4mg/kg), DFP (4 mg/kg), and Pilo (375 mg/kg) rats 
on the Novel Object Recognition Test (NORT). (A) No significant differences were 
observed in the exploration time during the identical object-sample phase test session 
between each set of groups. (B) POX, DFP, and Pilo rats displayed a significantly lower 
discrimination ratio when compared to age-matched control rats, indicating impaired 
recognition memory. Data expressed as mean ± SEM, * p < 0.05, t-test, n=8 
* 
* 
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CHAPTER 5: DISCUSSION 
 
 
Epidemiological data indicates that repeated exposure to OP pesticides [54, 171, 172] as 
well as a single acute exposure to nerve agents as seen in the survivors and first responders of the 
Tokyo subway sarin gas attack [173, 174] can lead to chronic neurological morbidities including 
cognitive deficits, mood disorders and depression. According to the Committee on Gulf War and 
Health, approximately 35% of soldiers deployed in the 1991 Persian Gulf War suffered from 
chronic multi-symptom illnesses characterized by depression and cognitive deficits. A leading 
cause for the Gulf War syndrome in these veterans is thought to be OP/nerve agent exposure 
during deployment [175]. SE is also known to produce cognitive deficits by affecting the 
hippocampus and changing the functional neuronal networks in the brain [176]. Our recent 
studies [137] along with the data presented here demonstrate that the POX and DFP models 
mimic both the acute hyper-cholinergic response and also exhibit chronic behavioral 
impairments and cognitive deficits in rats following OP intoxication. 
 
Numerous animal studies have documented the detrimental effects of pesticides exposure 
on neurobehavioral parameters [43, 177]. In these previous studies, however, only the acute 
effects of high-dose OP exposure were studied. For example, a single dose of malathion 
administered 30-min prior to behavioral tests produced deficits on FST and EPM paradigms 
[178]. In another study, behavioral effects of DFP intoxication were studied at 7 and 30-days 
post exposure. In the absence of any mortality, DFP rats exhibited deficits in FST but not on 
EPM [179]. In other studies, environmental OP exposures that are not associated with overt signs 
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of toxicity were mimicked by administering OPs such as chlorpyrifos, malathion, parathion or 
DFP at low doses chronically and conducting behavioral testing 7–30 days post exposure [46, 49, 
180-182]. Significant alterations in behavior and memory were noted in these animals using the 
behavioral tests also used in this study. In this project, we observed behavioral depression-like 
symptoms and cognitive deficits in rats months after a single severe POX, DFP, or Pilo exposure. 
Thus, the aims in this study successfully tested our central hypothesis that “Rats that have 
survive pilocarpine and OP-induced SE will exhibit chronic depression-like behavior and 
memory impairment.” To our knowledge, our study is the first report that demonstrates chronic 
neuropsychiatric deficits in rats surviving a severe OP exposure that are treated with standard 3-
drug atropine + 2-PAM + diazepam therapy. 
 
The hippocampus plays a major role in the limbic system, is essential in memory 
functioning [183] and also plays an important role in the pathophysiology of depression [184]. 
Ca
2+
 is a major second messenger and is vital to cellular signaling, developing neuronal plasticity 
which controls behavior, and memory [185, 186]. Thus, the levels of Ca
2+
 are tightly regulated 
by an intricate system of ion-channels, buffers, pumps and ER. Brief elevations in Ca
2+
 levels are 
critical to cellular communication and long-term potentiation (learning and memory 
consolidation). However, our research [187] and that of other investigators have demonstrated 
that sustained Ca
2+
 elevations particularly in the hippocampal region are detrimental to the cell 
and are implicated in many neurological disorders including Alzheimer's disease [188], 
Parkinson's disease [189], traumatic brain injury [190], aging [191], epilepsy [192], and stroke 
[193]. These neurological conditions are typically associated with cognitive deficits and other 
bio-behavioral disorders. In addition to the alterations in hippocampal Ca
2+
 dynamics, these 
 
 
52 
 
neurological disorders also exhibit neuronal damage in discreet brain regions. Brain lesion and 
neuropathology studies have demonstrated an association between neuronal injury and 
behavioral symptoms. For example, lesions to amygdalar interneurons in rats produce increased 
anxiety-like behaviors [194]. Lesions to specific hippocampal neurons produce cognitive deficits 
and anxiety [195]. Traumatic brain injury that damages neurons in the hippocampus, cortex and 
thalamus is often associated with cognitive deficits and depressive symptoms [196]. Ischemic 
insult such as those observed during stroke damages the hippocampus leading to an increased 
risk of post-stroke depression and memory impairments [197]. We recently reported neuronal 
damage in multiple brain regions including the hippocampus, amygdala, and cortex in a rat 
survival model of POX toxicity [143]. This wide-spread neuronal damage could possibly 
underlie the expression of behavioral deficits observed in severe POX toxicity survivors. 
 
We have previously reported that severe OP exposure is associated with N-methyl-D-
aspartate receptor dependent significant elevation in hippocampal neuronal calcium levels that 
lasted for weeks following the termination of OP induced SE [137, 143]. These sustained 
elevations in hippocampal neuronal calcium levels had its origins in Ca
2+
 release from 
intracellular stores in the endoplasmic reticulum, since blockade of intracellular Ca
2+
 induced 
Ca
2+
 release using inhibitors of ryanodine receptor and inositol trisphosphate receptor such as 
dantrolene, levetiracetam and carisbamate prevented the development of sustained Ca
2+
 plateau 
following OP toxicity [143]. It will be important to study whether these intracellular 
Ca
2+
 lowering agents when administered after severe OP exposure could also prevent or modify 
the symptoms of chronic morbidities. This model is ideal to study molecular mechanisms 
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underlying the development of long term neurological deficits and screen newer agents to limit 
mortality and morbidity following severe OP exposures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIST OF REFERENCES 
 
  
 
 
55 
 
 
 
 
 
List of References 
 
[1] Deshpande LS, Phillips K, Huang B, DeLorenzo RJ. Chronic behavioral and cognitive 
deficits in a rat survival model of paraoxon toxicity. Neurotoxicology 2014;44:352-7. 
[2] Munro N. Toxicity of the organophosphate chemical warfare agents GA, GB, and VX: 
implications for public protection. Environ Health Perspect 1994;102:18-38. 
[3] Bonner MR, Coble J, Blair A, Beane Freeman LE, Hoppin JA, Sandler DP et al. Malathion 
exposure and the incidence of cancer in the agricultural health study. Am J Epidemiol 
2007;166:1023-34. 
[4] Bronstein AC, Spyker DA, Cantilena LR,Jr, Green JL, Rumack BH, Giffin SL. 2008 Annual 
Report of the American Association of Poison Control Centers' National Poison Data 
System (NPDS): 26th Annual Report. Clin Toxicol (Phila) 2009;47:911-1084. 
[5] Eddleston M, Phillips MR. Self poisoning with pesticides. BMJ 2004;328:42-4. 
[6] Kumar SV, Fareedullah M, Sudhakar Y, Venkateswarlu B, Kumar EA. Current review on 
organophosphorus poisoning. Scholars Research Library, Archives of Applied Science 
Research 2010;2:2015,199-215. 
[7] De Silva HJ, Samarawickrema NA, Wickremasinghe AR. Toxicity due to organophosphorus 
compounds: what about chronic exposure? Trans R Soc Trop Med Hyg 2006;100:803-6. 
[8] Konradsen F. Acute pesticide poisoning--a global public health problem. Dan Med Bull 
2007;54:58-9. 
[9] Eyer P. The role of oximes in the management of organophosphorus pesticide poisoning. 
Toxicol Rev 2003;22:165-90. 
 
 
56 
 
[10] Bajgar J. Organophosphates/nerve agent poisoning: mechanism of action, diagnosis, 
prophylaxis, and treatment. Adv Clin Chem 2004;38:151-216. 
[11] McDonough JH,Jr, Dochterman LW, Smith CD, Shih TM. Protection against nerve agent-
induced neuropathology, but not cardiac pathology, is associated with the anticonvulsant 
action of drug treatment. Neurotoxicology 1995;16:123-32. 
[12] Deshpande SS, Smith CD, Filbert MG. Assessment of primary neuronal culture as a model 
for soman-induced neurotoxicity and effectiveness of memantine as a neuroprotective drug. 
Arch Toxicol 1995;69:384-90. 
[13] McDonough JH,Jr, McLeod CG,Jr, Nipwoda MT. Direct microinjection of soman or VX 
into the amygdala produces repetitive limbic convulsions and neuropathology. Brain Res 
1987;435:123-37. 
[14] Auer RN, Siesjo BK. Biological differences between ischemia, hypoglycemia, and epilepsy. 
Ann Neurol 1988;24:699-707. 
[15] Choi DW. Calcium-mediated neurotoxicity: relationship to specific channel types and role 
in ischemic damage. Trends Neurosci 1988;11:465-9. 
[16] Olney JW, Collins RC, Sloviter RS. Excitotoxic mechanisms of epileptic brain damage. 
Adv Neurol 1986;44:857-77. 
[17] Coudray-Lucas C, Prioux-Guyonneau M, Sentenac H, Cohen Y, Wepierre J. Brain 
catecholamine metabolism changes and hypothermia in intoxication by anticholinesterase 
agents. Acta Pharmacol Toxicol (Copenh) 1983;52:224-9. 
[18] Carpentier P, Foquin-Tarricone A, Bodjarian N, Rondouin G, Lerner-Natoli M, Kamenka 
JM et al. Anticonvulsant and antilethal effects of the phencyclidine derivative TCP in soman 
poisoning. Neurotoxicology 1994;15:837-51. 
[19] Goldman H, Berman RF, Hazlett J, Murphy S. Cerebrovascular responses to soman: time 
and dose dependent effects. Neurotoxicology 1993;14:469-83. 
 
 
57 
 
[20] Carpentier P, Delamanche IS, Le Bert M, Blanchet G, Bouchaud C. Seizure-related opening 
of the blood-brain barrier induced by soman: possible correlation with the acute 
neuropathology observed in poisoned rats. Neurotoxicology 1990;11:493-508. 
[21] Petras JM. Soman neurotoxicity. Fundam Appl Toxicol 1981;1:242. 
[22] Baze WB. Soman-induced morphological changes: an overview in the non-human primate. 
J Appl Toxicol 1993;13:173-7. 
[23] Hymowitz N, Ploshnick A, Laemle L, Brezenoff H. Effects of repeated administration of 
soman on schedule-controlled behavior and brain in the rat. Neurotoxicol Teratol 
1990;12:47-56. 
[24] McDonough JH,Jr, Shih TM. Pharmacological modulation of soman-induced seizures. 
Neurosci Biobehav Rev 1993;17:203-15. 
[25] Sparenborg S, Brennecke LH, Beers ET. Pharmacological dissociation of the motor and 
electrical aspects of convulsive status epilepticus induced by the cholinesterase inhibitor 
soman. Epilepsy Res 1993;14:95-103. 
[26] Martin LJ, Doebler JA, Shih TM, Anthony A. Protective effect of diazepam pretreatment on 
soman-induced brain lesion formation. Brain Res 1985;325:287-9. 
[27] Clement JG, Broxup B. Efficacy of diazepam and avizafone against soman-induced 
neuropathology in brain of rats. Neurotoxicology 1993;14:485-504. 
[28] Lallement G, Delamanche IS, Pernot-Marino I, Baubichon D, Denoyer M, Carpentier P et 
al. Neuroprotective activity of glutamate receptor antagonists against soman-induced 
hippocampal damage: quantification with an omega 3 site ligand. Brain Res 1993;618:227-
37. 
[29] Lallement G, Pernot-Marino I, Baubichon D, Burckhart MF, Carpentier P, Blanchet G. 
Modulation of soman-induced neuropathology with an anticonvulsant regimen. Neuroreport 
1994;5:2265-8. 
 
 
58 
 
[30] Myhrer T. Neuronal structures involved in the induction and propagation of seizures caused 
by nerve agents: implications for medical treatment. Toxicology 2007;239:1-14. 
[31] Vale JA. Toxicokinetic and toxicodynamic aspects of organophosphorus (OP) insecticide 
poisoning. Toxicol Lett 1998;102-103:649-52. 
[32] Council On Environmental Health. Pesticide exposure in children. Pediatrics 
2012;130:e1757-63. 
[33] Roberts JR, Karr CJ, Council On Environmental Health. Pesticide exposure in children. 
Pediatrics 2012;130:e1765-88. 
[34] Richardson JR, Taylor MM, Shalat SL, Guillot TS,3rd, Caudle WM, Hossain MM et al. 
Developmental pesticide exposure reproduces features of attention deficit hyperactivity 
disorder. FASEB J 2015. 
[35] Salvi RM, Lara DR, Ghisolfi ES, Portela LV, Dias RD, Souza DO. Neuropsychiatric 
evaluation in subjects chronically exposed to organophosphate pesticides. Toxicol Sci 
2003;72:267-71. 
[36] Stephens R, Spurgeon A, Calvert IA, Beach J, Levy LS, Berry H et al. Neuropsychological 
effects of long-term exposure to organophosphates in sheep dip. Lancet 1995;345:1135-9. 
[37] Amr MM, Halim ZS, Moussa SS. Psychiatric disorders among Egyptian pesticide 
applicators and formulators. Environ Res 1997;73:193-9. 
[38] Cohn J, MacPhail RC. Chlorpyrifos produces selective learning deficits in rats working 
under a schedule of repeated acquisition and performance. J Pharmacol Exp Ther 
1997;283:312-20. 
[39] Kassa J, Koupilova M, Vachek J. The influence of low-level sarin inhalation exposure on 
spatial memory in rats. Pharmacol Biochem Behav 2001;70:175-9. 
 
 
59 
 
[40] Prendergast MA, Terry AV,Jr, Buccafusco JJ. Chronic, low-level exposure to 
diisopropylfluorophosphate causes protracted impairment of spatial navigation learning. 
Psychopharmacology (Berl) 1997;129:183-91. 
[41] Bushnell PJ, Padilla SS, Ward T, Pope CN, Olszyk VB. Behavioral and neurochemical 
changes in rats dosed repeatedly with diisopropylfluorophosphate. J Pharmacol Exp Ther 
1991;256:741-50. 
[42] Tafuri J, Roberts J. Annals of Emergency Medicine 1987;16:193,-202. 
[43] Brown MA, Brix KA. Review of health consequences from high-, intermediate- and low-
level exposure to organophosphorus nerve agents. J Appl Toxicol 1998;18:393-408. 
[44] Rauh VA, Perera FP, Horton MK, Whyatt RM, Bansal R, Hao X et al. Brain anomalies in 
children exposed prenatally to a common organophosphate pesticide. Proc Natl Acad Sci U 
S A 2012;109:7871-6. 
[45] Ruckart PZ, Kakolewski K, Bove FJ, Kaye WE. Long-term neurobehavioral health effects 
of methyl parathion exposure in children in Mississippi and Ohio. Environ Health Perspect 
2004;112:46-51. 
[46] Ivens IA, Schmuck G, Machemer L. Learning and memory of rats after long-term 
administration of low doses of parathion. Toxicol Sci 1998;46:101-11. 
[47] Johnson FO, Chambers JE, Nail CA, Givaruangsawat S, Carr RL. Developmental 
chlorpyrifos and methyl parathion exposure alters radial-arm maze performance in juvenile 
and adult rats. Toxicol Sci 2009;109:132-42. 
[48] Levin ED, Timofeeva OA, Yang L, Petro A, Ryde IT, Wrench N et al. Early postnatal 
parathion exposure in rats causes sex-selective cognitive impairment and neurotransmitter 
defects which emerge in aging. Behav Brain Res 2010;208:319-27. 
 
 
60 
 
[49] Terry AV,Jr, Beck WD, Warner S, Vandenhuerk L, Callahan PM. Chronic impairments in 
spatial learning and memory in rats previously exposed to chlorpyrfos or 
diisopropylfluorophosphate. Neurotoxicol Teratol 2012;34:1-8. 
[50] Sanchez-Amate MC, Flores P, Sanchez-Santed F. Effects of chlorpyrifos in the plus-maze 
model of anxiety. Behav Pharmacol 2001;12:285-92. 
[51] Bushnell PJ, Pope CN, Padilla S. Behavioral and neurochemical effects of acute 
chlorpyrifos in rats: tolerance to prolonged inhibition of cholinesterase. J Pharmacol Exp 
Ther 1993;266:1007-17. 
[52] Bushnell PJ, Moser VC, Samsam TE. Comparing cognitive and screening tests for 
neurotoxicity. Effects of acute chlorpyrifos on visual signal detection and a neurobehavioral 
test battery in rats. Neurotoxicol Teratol 2001;23:33-44. 
[53] Yokoyama K, Araki S, Murata K, Nishikitani M, Okumura T, Ishimatsu S et al. Chronic 
neurobehavioral effects of Tokyo subway sarin poisoning in relation to posttraumatic stress 
disorder. Arch Environ Health 1998;53:249-56. 
[54] Rosenstock L, Keifer M, Daniell WE, McConnell R, Claypoole K. Chronic central nervous 
system effects of acute organophosphate pesticide intoxication. The Pesticide Health Effects 
Study Group. Lancet 1991;338:223-7. 
[55] Dassanayake T, Weerasinghe V, Dangahadeniya U, Kularatne K, Dawson A, Karalliedde L 
et al. Long-term event-related potential changes following organophosphorus insecticide 
poisoning. Clin Neurophysiol 2008;119:144-50. 
[56] Jamal GA. Neurological syndromes of organophosphorus compounds. Adverse Drug React 
Toxicol Rev 1997;16:133-70. 
[57] Singh S, Sharma N. Neurological syndromes following organophosphate poisoning. Neurol 
India 2000;48:308-13. 
 
 
61 
 
[58] Jamal GA, Hansen S, Julu PO. Low level exposures to organophosphorus esters may cause 
neurotoxicity. Toxicology 2002;181-182:23-33. 
[59] Sanchez-Santed F, Canadas F, Flores P, Lopez-Grancha M, Cardona D. Long-term 
functional neurotoxicity of paraoxon and chlorpyrifos: behavioural and pharmacological 
evidence. Neurotoxicol Teratol 2004;26:305-17. 
[60] Wright LK, Liu J, Nallapaneni A, Pope CN. Behavioral sequelae following acute 
diisopropylfluorophosphate intoxication in rats: comparative effects of atropine and 
cannabinomimetics. Neurotoxicol Teratol 2010;32:329-35. 
[61] Aas P. Future considerations for the medical management of nerve-agent intoxication. 
Prehosp Disaster Med 2003;18:208-16. 
[62] Doctor BP, Saxena A. Bioscavengers for the protection of humans against organophosphate 
toxicity. Chem Biol Interact 2005;157-158:167-71. 
[63] Raveh L, Grunwald J, Marcus D, Papier Y, Cohen E, Ashani Y. Human 
butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity. In vitro and 
in vivo quantitative characterization. Biochem Pharmacol 1993;45:2465-74. 
[64] Okumura T, Takasu N, Ishimatsu S, Miyanoki S, Mitsuhashi A, Kumada K et al. Report on 
640 victims of the Tokyo subway sarin attack. Ann Emerg Med 1996;28:129-35. 
[65] Balali-Mood M, Shariat M. Treatment of organophosphate poisoning. Experience of nerve 
agents and acute pesticide poisoning on the effects of oximes. J Physiol Paris 1998;92:375-
8. 
[66] Cherian A, Thomas SV. Status epilepticus. Ann Indian Acad Neurol 2009;12:140-53. 
[67] Reddy DS, Kuruba R. Experimental models of status epilepticus and neuronal injury for 
evaluation of therapeutic interventions. Int J Mol Sci 2013;14:18284-318. 
 
 
62 
 
[68] DeLorenzo RJ, Pellock JM, Towne AR, Boggs JG. Epidemiology of status epilepticus. J 
Clin Neurophysiol 1995;12:316-25. 
[69] Wiener SW, Hoffman RS. Nerve agents: a comprehensive review. J Intensive Care Med 
2004;19:22-37. 
[70] Tattersall J. Seizure activity post organophosphate exposure. Front Biosci (Landmark Ed) 
2009;14:3688-711. 
[71] Holstege CP, Kirk M, Sidell FR. Chemical warfare. Nerve agent poisoning. Crit Care Clin 
1997;13:923-42. 
[72] Yanagisawa N, Morita H, Nakajima T. Sarin experiences in Japan: acute toxicity and long-
term effects. J Neurol Sci 2006;249:76-85. 
[73] Nakajima T, Sato S, Morita H, Yanagisawa N. Sarin poisoning of a rescue team in the 
Matsumoto sarin incident in Japan. Occup Environ Med 1997;54:697-701. 
[74] Okudera H, Morita H, Iwashita T, Shibata T, Otagiri T, Kobayashi S et al. Unexpected 
nerve gas exposure in the city of Matsumoto: report of rescue activity in the first sarin gas 
terrorism. Am J Emerg Med 1997;15:527-8. 
[75] Tokuda Y, Kikuchi M, Takahashi O, Stein GH. Prehospital management of sarin nerve gas 
terrorism in urban settings: 10 years of progress after the Tokyo subway sarin attack. 
Resuscitation 2006;68:193-202. 
[76] Myhrer T, Enger S, Aas P. Efficacy of immediate and subsequent therapies against soman-
induced seizures and lethality in rats. Basic Clin Pharmacol Toxicol 2006;98:184-91. 
[77] Myhrer T, Skymoen LR, Aas P. Pharmacological agents, hippocampal EEG, and 
anticonvulsant effects on soman-induced seizures in rats. Neurotoxicology 2003;24:357-67. 
[78] Kapur J, Stringer JL, Lothman EW. Evidence that repetitive seizures in the hippocampus 
cause a lasting reduction of GABAergic inhibition. J Neurophysiol 1989;61:417-26. 
 
 
63 
 
[79] Kapur J, Lothman EW. Loss of inhibition precedes delayed spontaneous seizures in the 
hippocampus after tetanic electrical stimulation. J Neurophysiol 1989;61:427-34. 
[80] Kapur J, Macdonald RL. Rapid seizure-induced reduction of benzodiazepine and Zn2+ 
sensitivity of hippocampal dentate granule cell GABAA receptors. J Neurosci 
1997;17:7532-40. 
[81] Tonduli LS, Testylier G, Marino IP, Lallement G. Triggering of soman-induced seizures in 
rats: multiparametric analysis with special correlation between enzymatic, neurochemical 
and electrophysiological data. J Neurosci Res 1999;58:464-73. 
[82] Lallement G, Carpentier P, Collet A, Baubichon D, Pernot-Marino I, Blanchet G. 
Extracellular acetylcholine changes in rat limbic structures during soman-induced seizures. 
Neurotoxicology 1992;13:557-67. 
[83] Lallement G, Carpentier P, Collet A, Pernot-Marino I, Baubichon D, Blanchet G. Effects of 
soman-induced seizures on different extracellular amino acid levels and on glutamate uptake 
in rat hippocampus. Brain Res 1991;563:234-40. 
[84] Wade JV, Samson FE, Nelson SR, Pazdernik TL. Changes in extracellular amino acids 
during soman- and kainic acid-induced seizures. J Neurochem 1987;49:645-50. 
[85] McDonough JH,Jr, Shih TM. Neuropharmacological mechanisms of nerve agent-induced 
seizure and neuropathology. Neurosci Biobehav Rev 1997;21:559-79. 
[86] el-Etri MM, Nickell WT, Ennis M, Skau KA, Shipley MT. Brain norepinephrine reductions 
in soman-intoxicated rats: association with convulsions and AChE inhibition, time course, 
and relation to other monoamines. Exp Neurol 1992;118:153-63. 
[87] Shih TM, Capacio BR, Cook LA. Effects of anticholinergic-antiparkinsonian drugs on 
striatal neurotransmitter levels of rats intoxicated with soman. Pharmacol Biochem Behav 
1993;44:615-22. 
 
 
64 
 
[88] Fosbraey P, Wetherell JR, French MC. Neurotransmitter changes in guinea-pig brain 
regions following soman intoxication. J Neurochem 1990;54:72-9. 
[89] Liu DD, Ueno E, Ho IK, Hoskins B. Evidence that alterations in gamma-aminobutyric acid 
and acetylcholine in rat striata and cerebella are not related to soman-induced convulsions. J 
Neurochem 1988;51:181-7. 
[90] Ho IK, Fernando JC, Sivam SP, Hoskins B. Roles of dopamine and GABA in neurotoxicity 
of organophosphorus cholinesterase inhibitors. Proc West Pharmacol Soc 1984;27:177-80. 
[91] Towne AR, Pellock JM, Ko D, DeLorenzo RJ. Determinants of mortality in status 
epilepticus. Epilepsia 1994;35:27-34. 
[92] Meldrum BS. First Alfred Meyer Memorial Lecture. Epileptic brain damage: a consequence 
and a cause of seizures. Neuropathol Appl Neurobiol 1997;23:185,201; discussion 201-2. 
[93] Nevander G, Ingvar M, Auer R, Siesjo BK. Status epilepticus in well-oxygenated rats 
causes neuronal necrosis. Ann Neurol 1985;18:281-90. 
[94] Wasterlain CG, Fujikawa DG, Penix L, Sankar R. Pathophysiological mechanisms of brain 
damage from status epilepticus. Epilepsia 1993;34 Suppl 1:S37-53. 
[95] Scott RC. Status epilepticus in the developing brain: Long-term effects seen in humans. 
Epilepsia 2009;50 Suppl 12:32-3. 
[96] Kolfen W, Pehle K, Konig S. Is the long-term outcome of children following febrile 
convulsions favorable? Dev Med Child Neurol 1998;40:667-71. 
[97] Dam M. Children with epilepsy: the effect of seizures, syndromes, and etiological factors on 
cognitive functioning. Epilepsia 1990;31 Suppl 4:S26-9. 
[98] Aicardi J, Chevrie JJ. Convulsive status epilepticus in infants and children. A study of 239 
cases. Epilepsia 1970;11:187-97. 
 
 
65 
 
[99] Lacroix J, Deal C, Gauthier M, Rousseau E, Farrell CA. Admissions to a pediatric intensive 
care unit for status epilepticus: a 10-year experience. Crit Care Med 1994;22:827-32. 
[100] Sheppard E, Lippe S. Cognitive outcome of status epilepticus in children. Epilepsy Res 
Treat 2012;2012:984124. 
[101] Kubova H, Mares P, Suchomelova L, Brozek G, Druga R, Pitkanen A. Status epilepticus in 
immature rats leads to behavioural and cognitive impairment and epileptogenesis. Eur J 
Neurosci 2004;19:3255-65. 
[102] dos Santos NF, Arida RM, Filho EM, Priel MR, Cavalheiro EA. Epileptogenesis in 
immature rats following recurrent status epilepticus. Brain Res Brain Res Rev 2000;32:269-
76. 
[103] Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T et al. Guidelines for the 
evaluation and management of status epilepticus. Neurocrit Care 2012;17:3-23. 
[104] Mayer SA, Claassen J, Lokin J, Mendelsohn F, Dennis LJ, Fitzsimmons BF. Refractory 
status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol 
2002;59:205-10. 
[105] Wheless JW, Treiman DM. The role of the newer antiepileptic drugs in the treatment of 
generalized convulsive status epilepticus. Epilepsia 2008;49 Suppl 9:74-8. 
[106] Newmark J. Nerve agents. Neurol Clin 2005;23:623-41. 
[107] Newmark J. Nerve agents. Neurologist 2007;13:20-32. 
[108] Newmark J. Nerve agents: pathophysiology and treatment of poisoning. Semin Neurol 
2004;24:185-96. 
[109] McDonough JH, Benjamin A, McMonagle JD, Rowland T, Shih TM. Effects of 
fosphenytoin on nerve agent-induced status epilepticus. Drug Chem Toxicol 2004;27:27-39. 
 
 
66 
 
[110] McDonough JH,Jr, McMonagle J, Copeland T, Zoeffel D, Shih TM. Comparative 
evaluation of benzodiazepines for control of soman-induced seizures. Arch Toxicol 
1999;73:473-8. 
[111] Shih T, McDonough JH,Jr, Koplovitz I. Anticonvulsants for soman-induced seizure 
activity. J Biomed Sci 1999;6:86-96. 
[112] Marrs TC. Diazepam in the treatment of organophosphorus ester pesticide poisoning. 
Toxicol Rev 2003;22:75-81. 
[113] Eddleston M, Buckley NA, Eyer P, Dawson AH. Management of acute organophosphorus 
pesticide poisoning. Lancet 2008;371:597-607. 
[114] Abebe M. Organophosphate pesticide poisoning in 50 Ethiopian patients. Ethiop Med J 
1991;29:109-18. 
[115] Barthold CL, Schier JG. Organic phosphorus compounds--nerve agents. Crit Care Clin 
2005;21:673,89, v-vi. 
[116] Cannard K. The acute treatment of nerve agent exposure. J Neurol Sci 2006;249:86-94. 
[117] Rudolph U, Mohler H. Analysis of GABAA receptor function and dissection of the 
pharmacology of benzodiazepines and general anesthetics through mouse genetics. Annu 
Rev Pharmacol Toxicol 2004;44:475-98. 
[118] Gilat E, Kadar T, Levy A, Rabinovitz I, Cohen G, Kapon Y et al. Anticonvulsant treatment 
of sarin-induced seizures with nasal midazolam: an electrographic, behavioral, and 
histological study in freely moving rats. Toxicol Appl Pharmacol 2005;209:74-85. 
[119] Forster A, Gardaz JP, Suter PM, Gemperle M. Respiratory depression by midazolam and 
diazepam. Anesthesiology 1980;53:494-7. 
[120] Sidell FR, Borak J. Chemical warfare agents: II. Nerve agents. Ann Emerg Med 
1992;21:865-71. 
 
 
67 
 
[121] Dickson EW, Bird SB, Gaspari RJ, Boyer EW, Ferris CF. Diazepam inhibits 
organophosphate-induced central respiratory depression. Acad Emerg Med 2003;10:1303-6. 
[122] Murphy MR, Blick DW, Dunn MA, Fanton JW, Hartgraves SL. Diazepam as a treatment 
for nerve agent poisoning in primates. Aviat Space Environ Med 1993;64:110-5. 
[123] Shih TM, Koviak TA, Capacio BR. Anticonvulsants for poisoning by the 
organophosphorus compound soman: pharmacological mechanisms. Neurosci Biobehav 
Rev 1991;15:349-62. 
[124] Yamagata Y, Imoto K, Obata K. A mechanism for the inactivation of Ca2+/calmodulin-
dependent protein kinase II during prolonged seizure activity and its consequence after the 
recovery from seizure activity in rats in vivo. Neuroscience 2006;140:981-92. 
[125] DeLorenzo RJ, Sun DA. Basic mechanisms in status epilepticus: role of calcium in 
neuronal injury and the induction of epileptogenesis. Adv Neurol 2006;97:187-97. 
[126] Lee S, Williamson J, Lothman EW, Szele FG, Chesselet MF, Von Hagen S et al. Early 
induction of mRNA for calbindin-D28k and BDNF but not NT-3 in rat hippocampus after 
kainic acid treatment. Brain Res Mol Brain Res 1997;47:183-94. 
[127] Coulter DA, McIntyre DC, Loscher W. Animal models of limbic epilepsies: what can they 
tell us? Brain Pathol 2002;12:240-56. 
[128] Groticke I, Hoffmann K, Loscher W. Behavioral alterations in the pilocarpine model of 
temporal lobe epilepsy in mice. Exp Neurol 2007;207:329-49. 
[129] Kulig K, Malawska B. Carisbamate, a new carbamate for the treatment of epilepsy. IDrugs 
2007;10:720-7. 
[130] Hort J, Brozek G, Mares P, Langmeier M, Komarek V. Cognitive functions after 
pilocarpine-induced status epilepticus: changes during silent period precede appearance of 
spontaneous recurrent seizures. Epilepsia 1999;40:1177-83. 
 
 
68 
 
[131] Lenck-Santini PP. Cognitive and behavioral comorbidities in epilepsy: the treacherous 
nature of animal models. Epilepsy Curr 2013;13:182-3. 
[132] Turski WA, Cavalheiro EA, Schwarz M, Czuczwar SJ, Kleinrok Z, Turski L. Limbic 
seizures produced by pilocarpine in rats: behavioural, electroencephalographic and 
neuropathological study. Behav Brain Res 1983;9:315-35. 
[133] Turski WA, Czuczwar SJ, Kleinrok Z, Schwarz M, Turski L. Intraamygdaloid morphine 
produces seizures and brain damage in rats. Life Sci 1983;33 Suppl 1:615-8. 
[134] Turski WA, Cavalheiro EA, Turski L, Kleinrok Z. Intrahippocampal bethanechol in rats: 
behavioural, electroencephalographic and neuropathological correlates. Behav Brain Res 
1983;7:361-70. 
[135] Turski WA, Czuczwar SJ, Kleinrok Z, Turski L. Cholinomimetics produce seizures and 
brain damage in rats. Experientia 1983;39:1408-11. 
[136] Nagarkatti N, Deshpande LS, Carter DS, DeLorenzo RJ. Dantrolene inhibits the calcium 
plateau and prevents the development of spontaneous recurrent epileptiform discharges 
following in vitro status epilepticus. Eur J Neurosci 2010;32:80-8. 
[137] Deshpande LS, Carter DS, Blair RE, DeLorenzo RJ. Development of a prolonged calcium 
plateau in hippocampal neurons in rats surviving status epilepticus induced by the 
organophosphate diisopropylfluorophosphate. Toxicol Sci 2010;116:623-31. 
[138] Raza M, Pal S, Rafiq A, DeLorenzo RJ. Long-term alteration of calcium homeostatic 
mechanisms in the pilocarpine model of temporal lobe epilepsy. Brain Res 2001;903:1-12. 
[139] Carter DS, Harrison AJ, Falenski KW, Blair RE, DeLorenzo RJ. Long-term decrease in 
calbindin-D28K expression in the hippocampus of epileptic rats following pilocarpine-
induced status epilepticus. Epilepsy Res 2008;79:213-23. 
 
 
69 
 
[140] McDonough JH,Jr, Zoeffel LD, McMonagle J, Copeland TL, Smith CD, Shih TM. 
Anticonvulsant treatment of nerve agent seizures: anticholinergics versus diazepam in 
soman-intoxicated guinea pigs. Epilepsy Res 2000;38:1-14. 
[141] Reuben M, Cooper S. Chemical Watch Factsheet  - Parathion. 2007. 
[142] Lewis RJ. In: Anonymous   <br />Sax's Dangerous Properties of Industrial Materials: 
John Wiley and Sons, Inc; 2014, p. 2457-2458. 
[143] Deshpande LS, Carter DS, Phillips KF, Blair RE, DeLorenzo RJ. Development of status 
epilepticus, sustained calcium elevations and neuronal injury in a rat survival model of 
lethal paraoxon intoxication. Neurotoxicology 2014;44:17-26. 
[144] Terry AV,Jr, Buccafusco JJ, Gearhart DA, Beck WD, Middlemore-Risher ML, Truan JN 
et al. Repeated, intermittent exposures to diisopropylfluorophosphate in rats: protracted 
effects on cholinergic markers, nerve growth factor-related proteins, and cognitive function. 
Neuroscience 2011;176:237-53. 
[145] Gura S, Tzanani N, Hershkovitz M, Barak R, Dagan S. Fate of the chemical warfare agent 
VX in asphalt: a novel approach for the quantitation of VX in organic surfaces. Arch 
Environ Contam Toxicol 2006;51:1-10. 
[146] Sivam SP, Hoskins B, Ho IK. An assessment of comparative acute toxicity of diisopropyl-
fluorophosphate, tabun, sarin, and soman in relation to cholinergic and GABAergic enzyme 
activities in rats. Fundam Appl Toxicol 1984;4:531-8. 
[147] Gardner R, Ray R, Frankenheim J, Wallace K, Loss M, Robichaud R. A possible 
mechanism for diisopropylfluorophosphate-induced memory loss in rats. Pharmacol 
Biochem Behav 1984;21:43-6. 
[148] Willner P, Towell A, Sampson D, Sophokleous S, Muscat R. Reduction of sucrose 
preference by chronic unpredictable mild stress, and its restoration by a tricyclic 
antidepressant. Psychopharmacology (Berl) 1987;93:358-64. 
 
 
70 
 
[149] Mazarati A, Siddarth P, Baldwin RA, Shin D, Caplan R, Sankar R. Depression after status 
epilepticus: behavioural and biochemical deficits and effects of fluoxetine. Brain 
2008;131:2071-83. 
[150] Palanza P. Animal models of anxiety and depression: how are females different? Neurosci 
Biobehav Rev 2001;25:219-33. 
[151] Heredia L, Belles M, Llovet MI, Domingo JL, Linares V. Neurobehavioral effects of 
concurrent exposure to cesium-137 and paraquat during neonatal development in mice. 
Toxicology 2015;329:73-9. 
[152] Pellow S, Chopin P, File SE, Briley M. Validation of open:closed arm entries in an 
elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985;14:149-67. 
[153] Walf AA, Frye CA. The use of the elevated plus maze as an assay of anxiety-related 
behavior in rodents. Nat Protoc 2007;2:322-8. 
[154] Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for 
antidepressants. Arch Int Pharmacodyn Ther 1977;229:327-36. 
[155] Krishnan V, Nestler EJ, Krishnan V, Nestler EJ. The molecular neurobiology of 
depression. Nature;455:894. 
[156] Pucilowski O, Overstreet DH. Effect of chronic antidepressant treatment on responses to 
apomorphine in selectively bred rat strains. Brain Res Bull 1993;32:471-5. 
[157] Mazarati A, Shin D, Auvin S, Caplan R, Sankar R. Kindling epileptogenesis in immature 
rats leads to persistent depressive behavior. Epilepsy & Behavior 2007;10:377-83. 
[158] Antunes M, Biala G. The novel object recognition memory: neurobiology, test procedure, 
and its modifications. Cogn Process 2012;13:93-110. 
 
 
71 
 
[159] Clifford DB, Olney JW, Maniotis A, Collins RC, Zorumski CF. The functional anatomy 
and pathology of lithium-pilocarpine and high-dose pilocarpine seizures. Neuroscience 
1987;23:953-68. 
[160] Broomfield CA, Kirby SD. Progress on the road to new nerve agent treatments. J Appl 
Toxicol 2001;21 Suppl 1:S43-6. 
[161] Golomb BA. Acetylcholinesterase inhibitors and Gulf War illnesses. Proc Natl Acad Sci U 
S A 2008;105:4295-300. 
[162] Overstreet DH. Modeling depression in animal models. Methods Mol Biol 2012;829:125-
44. 
[163] Mazarati AM, Shin D, Kwon YS, Bragin A, Pineda E, Tio D et al. Elevated plasma 
corticosterone level and depressive behavior in experimental temporal lobe epilepsy. 
Neurobiol Dis 2009;34:457-61. 
[164] Strekalova T, Gorenkova N, Schunk E, Dolgov O, Bartsch D. Selective effects of 
citalopram in a mouse model of stress-induced anhedonia with a control for chronic stress. 
Behav Pharmacol 2006;17:271-87. 
[165] Walf AA, Frye AC. Using the Elevated Plus Maze as a Bioassay to Assess the Effects of 
Naturally Occurring and Exogenously Administered Compounds to Influence Anxiety-
Related Behaviors of Mice. In: Gould TD, editor. Mood and Anxiety Related Phenotypes in 
Mice: Humana Press; 2009, p. 225-246. 
[166] Slattery DA, Cryan JF. Using the rat forced swim test to assess antidepressant-like activity 
in rodents. Nat Protoc 2012;7:1009-14. 
[167] Slotkin TA. Does early-life exposure to organophosphate insecticides lead to prediabetes 
and obesity? Reprod Toxicol 2011;31:297-301. 
[168] Gupta RP, Abou-Donia MB. Enhanced activity and level of protein kinase A in the spinal 
cord supernatant of diisopropyl phosphorofluoridate (DFP)-treated hens. Distribution of 
 
 
72 
 
protein kinases and phosphatases in spinal cord subcellular fractions. Mol Cell Biochem 
2001;220:15-23. 
[169] Deshpande LS, Sun DA, Sombati S, Baranova A, Wilson MS, Attkisson E et al. 
Alterations in neuronal calcium levels are associated with cognitive deficits after traumatic 
brain injury. Neurosci Lett 2008;441:115-9. 
[170] Bevins RA, Besheer J. Object recognition in rats and mice: a one-trial non-matching-to-
sample learning task to study 'recognition memory'. Nat Protoc 2006;1:1306-11. 
[171] Savage DD, Rigsbee LC, McNamara JO. Knife cuts of entorhinal cortex: effects on 
development of amygdaloid kindling and seizure-induced decrease of muscarinic 
cholinergic receptors. J Neurosci 1985;5:408-13. 
[172] Wesseling C, Keifer M, Ahlbom A, McConnell R, Moon JD, Rosenstock L et al. Long-
term neurobehavioral effects of mild poisonings with organophosphate and n-methyl 
carbamate pesticides among banana workers. Int J Occup Environ Health 2002;8:27-34. 
[173] Hood E. The Tokyo attacks in retrospect: sarin leads to memory loss. Environ Health 
Perspect 2001;109:A542. 
[174] Miyaki K, Nishiwaki Y, Maekawa K, Ogawa Y, Asukai N, Yoshimura K et al. Effects of 
sarin on the nervous system of subway workers seven years after the Tokyo subway sarin 
attack. J Occup Health 2005;47:299-304. 
[175] Brimfield AA. Chemicals of military deployments: revisiting Gulf War Syndrome in light 
of new information. Prog Mol Biol Transl Sci 2012;112:209-30. 
[176] Tyler AL, Mahoney JM, Richard GR, Holmes GL, Lenck-Santini PP, Scott RC. Functional 
network changes in hippocampal CA1 after status epilepticus predict spatial memory 
deficits in rats. J Neurosci 2012;32:11365-76. 
 
 
73 
 
[177] Burns CJ, McIntosh LJ, Mink PJ, Jurek AM, Li AA. Pesticide exposure and 
neurodevelopmental outcomes: review of the epidemiologic and animal studies. J Toxicol 
Environ Health B Crit Rev 2013;16:127-283. 
[178] Assini FL, Zanette KD, Brocardo PS, Pandolfo P, Rodrigues AL, Takahashi RN. 
Behavioral effects and ChE measures after acute and repeated administration of malathion 
in rats. Environ Toxicol Pharmacol 2005;20:443-9. 
[179] Wright LK, Liu J, Nallapaneni A, Pope CN. Behavioral sequelae following acute 
diisopropylfluorophosphate intoxication in rats: comparative effects of atropine and 
cannabinomimetics. Neurotoxicol Teratol 2010;32:329-35. 
[180] Lima CS, Ribeiro-Carvalho A, Filgueiras CC, Manhaes AC, Meyer A, Abreu-Villaca Y. 
Exposure to methamidophos at adulthood elicits depressive-like behavior in mice. 
Neurotoxicology 2009;30:471-8. 
[181] Timofeeva OA, Sanders D, Seemann K, Yang L, Hermanson D, Regenbogen S et al. 
Persistent behavioral alterations in rats neonatally exposed to low doses of the 
organophosphate pesticide, parathion. Brain Res Bull 2008;77:404-11. 
[182] Yan C, Jiao L, Zhao J, Yang H, Peng S. Repeated exposures to chlorpyrifos lead to spatial 
memory retrieval impairment and motor activity alteration. Neurotoxicol Teratol 
2012;34:442-9. 
[183] Battaglia FP, Benchenane K, Sirota A, Pennartz CM, Wiener SI. The hippocampus: hub of 
brain network communication for memory. Trends Cogn Sci 2011;15:310-8. 
[184] Campbell S, Macqueen G. The role of the hippocampus in the pathophysiology of major 
depression. J Psychiatry Neurosci 2004;29:417-26. 
[185] Baker KD, Edwards TM, Rickard NS. The role of intracellular calcium stores in synaptic 
plasticity and memory consolidation. Neurosci Biobehav Rev 2013;37:1211-39. 
 
 
74 
 
[186] Bading H, Ginty DD, Greenberg ME. Regulation of gene expression in hippocampal 
neurons by distinct calcium signaling pathways. Science 1993;260:181-6. 
[187] Delorenzo RJ, Sun DA, Deshpande LS. Cellular mechanisms underlying acquired 
epilepsy: the calcium hypothesis of the induction and maintainance of epilepsy. Pharmacol 
Ther 2005;105:229-66. 
[188] Chadwick W, Mitchell N, Martin B, Maudsley S. Therapeutic targeting of the endoplasmic 
reticulum in Alzheimer's disease. Curr Alzheimer Res 2012;9:110-9. 
[189] Surmeier DJ, Schumacker PT. Calcium, bioenergetics, and neuronal vulnerability in 
Parkinson's disease. J Biol Chem 2013;288:10736-41. 
[190] Sun DA, Deshpande LS, Sombati S, Baranova A, Wilson MS, Hamm RJ et al. Traumatic 
brain injury causes a long-lasting calcium (Ca2+)-plateau of elevated intracellular Ca levels 
and altered Ca2+ homeostatic mechanisms in hippocampal neurons surviving brain injury. 
Eur J Neurosci 2008;27:1659-72. 
[191] Raza M, Deshpande LS, Blair RE, Carter DS, Sombati S, DeLorenzo RJ. Aging is 
associated with elevated intracellular calcium levels and altered calcium homeostatic 
mechanisms in hippocampal neurons. Neurosci Lett 2007;418:77-81. 
[192] Nagarkatti N, Deshpande LS, DeLorenzo RJ. Development of the calcium plateau 
following status epilepticus: role of calcium in epileptogenesis. Expert Rev Neurother 
2009;9:813-24. 
[193] Deshpande LS, Limbrick DD,Jr, Sombati S, DeLorenzo RJ. Activation of a novel injury-
induced calcium-permeable channel that plays a key role in causing extended neuronal 
depolarization and initiating neuronal death in excitotoxic neuronal injury. J Pharmacol Exp 
Ther 2007;322:443-52. 
[194] Truitt WA, Johnson PL, Dietrich AD, Fitz SD, Shekhar A. Anxiety-like behavior is 
modulated by a discrete subpopulation of interneurons in the basolateral amygdala. 
Neuroscience 2009;160:284-94. 
 
 
75 
 
[195] Barkus C, McHugh SB, Sprengel R, Seeburg PH, Rawlins JN, Bannerman DM. 
Hippocampal NMDA receptors and anxiety: at the interface between cognition and emotion. 
Eur J Pharmacol 2010;626:49-56. 
[196] Raghupathi R. Cell death mechanisms following traumatic brain injury. Brain Pathol 
2004;14:215-22. 
[197] Loubinoux I, Kronenberg G, Endres M, Schumann-Bard P, Freret T, Filipkowski RK et al. 
Post-stroke depression: mechanisms, translation and therapy. J Cell Mol Med 2012;16:1961-
9. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
76 
 
 
 
 
 
Vita 
 
 
Beverly Ann Huang was born on July 8, 1986 in Ann Arbor, Michigan, and is an American 
citizen. She grew up in Middletown, NJ, and graduated from Middletown High School South in 
2004. She received her Bachelor of Arts in Neuroscience from The Johns Hopkins University in 
Baltimore, Maryland, in 2008, and worked as a laboratory manager for 2 additional years in 
Baltimore before moving to Richmond, Virginia. 
 
 
 
 
 
 
 
